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ABSTRACT 
 
 Chemokines are structurally and functionally related 8-10 kDa proteins 
defined by four conserved cysteine residues. They consist of a superfamily of 
proinflammatory mediators that promote the recruitment of various kinds of 
leukocytes and other cell types through binding to their respective chemokine 
receptor, a member of the GPCR family. Abnormal control of this system results 
in various diseases including tumorigenesis and cancer metastasis. Deregulation 
can occur when constitutively active mutant (CAM) chemokine receptors are 
locked in the “on” position. This can lead to cellular transformation/tumorigenesis. 
A viral CAM receptor, ORF74, that can cause tumors in humans, also has 
homology to human CXC chemokine receptor 2 (CXCR2), which is a G-protein-
coupled receptor (GPCR) expressed on neutrophils, some monocytes, 
endothelial cells, and some epithelial cells. CXCR2 activation with ELR+ CXC 
chemokines induces leukocyte migration, trafficking, cellular differentiation, 
angiogenesis and cellular transformation. Using a high throughput yeast screen 
we identified a novel point mutation, D9H, in CXCR2, which leads to constitutive 
activation (CA). Generation of positively charged substitutions, D9K and D9R, 
and D143V as a positive control resulted in CA CXCR2 with differential levels of 
cellular transformation. To further investigate how D9 mutations lead to 
differential CA, we used inhibitors of known signal transduction pathways. 
Pertusiss toxin (PTX) sensitivity in foci formation assays demonstrated that D9R 
uses the Gi subunit like WTCXCR2 and D143V, while D9H and D9K do not. All 
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CA receptors use the JAK pathway based on sensitivity to the inhibitor, AG490. 
Phosphorylation of PLC-beta 3 and sensitivity to the PLC-beta 3 inhibitor, 
U73122, implicates that mutant receptors such as D143V, D9H, D9K, and D9R 
utilize the Gq/11 subunit. Interestingly, D9R use both Gi and Gq/11 subunits. All of 
the CA receptors induced phosphorylation of the epidermal growth factor 
receptor (EGFR) indicating a transactivation between CXCR2 and EGFR. These 
data describe two novel and important findings. First, N-terminal CXCR2 controls 
activation and signaling using multiple G protein subunits to elicit downstream 
signaling. Second, our work supports the “functional selectivity” model for GPCR 
activation. That is, mimicking agonist activation, CA CXCR2 receptors have 
multiple conformational states that lead to differential activation. 
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PART I. GENERAL INTRODUCTION 
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CHAPTER 1. G PROTEIN-COUPLED RECEPTORS 
 
An Overview 
 Since the structure of the G-protein coupled receptor (GPCR), rhodopsin 
was crystallized and solved [1] [2], technological advances have expanded the 
structure and function of GPCR superfamilies. Also, the number of identified 
GPCRs has grown rapidly and now consists of nearly 1,500 unique full-length 
members [3-5]. GPCRs are one of the largest and most diverse groups of 
proteins in the human genome [4, 6].  These proteins can bind to a broad range 
of exogenous stimuli including light, odor, and taste [6, 7], as well as endogenous 
ligands including peptides and hormones (e.g. angiotensin, bradykinin, 
endothelin, and melanocortin), biogenic amines (e.g. adrenaline, dopamine, 
histamine, and serotonin), nucleosides and nucleotides (e.g. adenosine, 
adenosine triphosphate, and uridine triphosphate), peptide pheromones (e.g. 
alpha-factor and a-factor in a variety of fungi), and lipids and eicosanoids (e.g. 
cannabinoids, leukotrienes, prostaglandins, and thromboxanes) [8] (Table 1 and 
Figure 1).  
 GPCRs play an important role as a physical conduit of extracellular 
signals across the cellular membrane inducing complex biological processes and 
function through intracellular heterotrimeric G proteins [9-11]. G proteins are 
comprised of non-identical α (~33-35 kDa), β (~35 kDa), and γ (~15 kDa) 
subunits [5].  
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Table 1. Sequence-based groupings within the G-protein-coupled receptors    
 
 
Abbreviation: PTH, Parathyroid hormone receptor; PTHrP, Parathyroid hormone 
related peptide receptor; GABAb, γ-Aminobutyric acid receptor 
Modified from Flower et al [12]. 
Class: A Rhodopsin-like receptors  
Family I 
Olfactory receptors, adenosine receptors,  
melanocortin receptors, and others 
Family II Biogenic amine receptors 
Family III Vertebrate opsins and neuropeptide receptors 
Family IV Invertebrate opsins 
Family V Chemokine, chemotactic, somatostatin, opioids and others 
Family VI Melatonin receptors and others 
Class B: Calcitonin and related receptors 
Family I Calcitonin and calcitonin-like receptors 
Family II PTH/PTHrP receptors 
Family III Glucagon, secretin receptors and others 
Family IV Latrotoxin receptors and others 
Class C: Metabotropic glutamate and related receptors 
Family I Metabotropic glutamate receptors 
Family II Calcium receptors 
Family II GABAb receptors 
Family IV Putative pheromone receptors 
Class D: STE2 pheromone receptors 
Class E: STE3 pheromone receptors 
Class F: cAMP and archaebacterial opsin receptors 
	   4	  
 
Figure 1. Classification and diversity of GPCRs.  
Class A GPCRs are characterized by several highly conserved amino acids in 
the TMs and there is usually a disulfide bridge linking extracellular loops 1 and 2. 
Most of the class A receptors have a palmitoylated cysteine residue in the 
intracellular C-terminal tail. The binding sites of the endogenous small-molecule 
hormone ligands of class A GPCRs are located within the 7 TM bundle (A-1, the 
ligand binding site is indicated in orange). For peptide and glycoprotein hormone 
receptors (A-2 and A-3, respectively), binding occurs at the N terminus, the 
extracellular loop segments and the extracellular domains of the TM helices. 
Class B GPCRs contain a relatively long N-terminal tail (B). The class B 
receptors show a number of conserved proline residues within the TMs. The 
majority of class C receptors are characterized by very large N- and C-terminal 
tails, a disulfide bridge connecting the first and second extracellular loops, 
together with a very short and well-conserved third intracellular loop (C). A 
number of the highly conserved residues of class A GPCRs are also strongly 
conserved in class C GPCRs. The ligand binding site is located in the N-terminal 
domain, which is composed of the so-called venus flytrap (VFT, gray color filled 
region) module that shares sequence similarity with bacterial periplasmic amino 
acid binding proteins. In all class C GPCRs except the GABAb receptor, a 
cysteine-rich domain (CRD), which contains nine conserved cysteine residues, 
links the VFT to the 7 TM domain.  
Modified from Jacoby et al [13]. 
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Mammalian G proteins are comprised of one of 17 α-subunits combined with one 
of 5 β-subunits and one of 12 γ-subunits, which provides an extraordinary 
combinatorial potential for inducing signal transduction pathways [5, 14] (Table 
2). 
 The common structural features of GPCRs are seven transmembrane 
(TM)-spanning α-helical domains, an extracellular N-terminus, an intracellular C-
terminus, and three loops on each side of the membrane [9]. Interaction of the 
GPCRs with their ligands causes a conformational alteration, which induces the 
dissociation of the G protein α-subunit from the GPCR and the βγ-subunit leading 
to the exchange of GDP with GTP [15, 16].  Activation of the G proteins transmits 
a signal through effectors, such as adenylyl cyclase and phospholipase Cβ [5] 
(Table 3). 
Because of the high degree of selectivity and sensitivity between GPCRs 
and their ligands, they function as key modulators for complex biological 
processes such as neurotransmission, hormone and enzyme release from 
endocrine and exocrine glands, immune responses, cardiac- and smooth-muscle 
contraction and blood pressure regulation.  Malfunction of GPCR mediated 
processes can lead to a variety of disorders including cancer development and 
progression [17-19]. Considering the broad range of GPCR-modulated biological 
processes, GPCRs are attractive drug targets for pharmaceutical companies. In 
fact, they are the top target proteins for pharmaceutical discovery programs [20].  
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Table 2. The class and subunits of heterotrimeric G proteins, gene names 
and localization in mammalian cells. 
 
 
to be continued on the next page 
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Table 2-continued. The class and subunits of heterotrimeric G proteins, 
gene names and localization in mammalian cells. 
 
Modified from Malbon [5] 
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Table 3. Heterotrimeric G-protein subunits and their functions.  
 
 
Abbreviation: GRK, G-protein receptor kinase. Modified from Malbon [5]. 
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Currently GPCRs are the molecular targets of about 30% of all marketed drugs, 
50% of all modern prescription drugs, and 25% of the top-selling drugs [13, 21, 
22]. Moreover only approximately 30% of all known GPCRs, mainly in the 
biogenic amine family (a subfamily of class 1 GPCRs), have been targeted with 
drugs. However, many novel GPCRs have been reported as ‘orphan’ receptors 
because their function and endogenous ligands are still unknown [21, 23, 24]. 
Research on GPCRs could potentially contribute to our understanding and 




GPCR activation is induced by a variety of ligands [4, 8]. The focus of 
GPCR research is the identification of the binding domains for ligands using 
genetic, biochemical, and biophysical techniques. For understanding the 
structure-function relationship between GPCRs and their ligands, molecular 
techniques such as site-directed or random mutagenesis, domain swapping, and 
the use of labeled probes have been used to identify the important residues and 
domains [25].  The binding sites of endogenous “small-molecule” ligands in 
family 1 receptors, such as for the retinal chromophore in rhodopsin and 
catecholamines in the adrenergic receptors have well characterized receptor-
binding domains [26-28]. Recent studies on the binding domains of peptide 
receptors such as the receptors for angiotensin [29-31], parathyroid hormone [32, 
33], secretin [34], bradykinin B2 [35, 36], gonadotropin-releasing hormone [37], 
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opioids [38, 39], neurokinin (NK) [40, 41], vasopressin/oxytosin [42-44], 
cholecystokin/gastrin [45, 46], and neurotensin 1 [47] have been extended into 
other classes of GPCRs.  Although there are some common features among 
ligands, there are a variety of unique interactions between GPCRs and their 
cognate ligands. For instance, large ligands, including proteins, bind to 
extracellular loops, whereas small molecules ligands, such as pharmacological 
agents, bind within the TM region of GPCRs (Figure 1). Peptides ligands present 
a combination of the two processes. The peptides primarily bind to the 
extracellular loops and part of the ligand may penetrate into the transmembrane 
region at the same time and interact with residues buried within the lipid bilayer 
[48-51].  
Before the crystal structure of ligand-activated human β2 adrenergic 
receptor (β2AR) was solved [52], simplistic models were generated where 
GPCRs were simple binary switches that could be in either an inactive and active 
forms. However, GPCRs are no longer considered simple ON/OFF switches. 
Instead they are more like rheostats that are dynamic and assume many different 
conformations [53, 54].  Recently, multi-state models suggest that GPCRs 
spontaneously shift between multiple active and inactive conformations in order 
to explain their complex GPCR activation states [55, 56]. The 5-HT2-serotonin 
receptors [57] α2A-adrenoceptors [58], AT1 receptor [59], gonadotropin-releasing 
hormone receptors [60], µ-opioid receptors [61] and many others have different 
receptor conformations supporting the multi-state model. Based on the multi-
state model, the concept of ‘functional selectivity,’ ‘agonist-directed trafficking’, or 
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‘biased agonism’ have been used to describe how different ligands for a specific 
receptor can induce different conformations of the receptor [62]. Recently, the 
these different terms have been narrowed to either ‘functional selectivity’ or 
‘ligand-induced differential signaling’ to describe this phenomenon [63].  
 In addition to functional selectivity, ‘ligand efficacy’ addresses the complex 
functional behavior of GPCRs. Ligand efficacy is used to describe the effect of a 
ligand on the structure and biophysical properties of a receptor [55]. Natural and 
synthetic ligands can be divided into four different efficacy classes: ‘full agonists’ 
are able to maximally activate the receptor; ‘partial agonists’ induce submaximal 
activation even at saturating concentrations; ‘neutral antagonists’ show no effect 
on signaling activity but can prevent other ligands from binding to the receptor; 
‘inverse agonist’ decrease basal or constitutive activity [55]. 
 
GPCR Signaling 
Initially, G proteins were described as guanine-nucleotide regulatory 
proteins that functionally link the receptor with effectors.   The initial description of 
G proteins was glucagon stimulation of adenylyl cyclase through the secondary 
effector cyclic AMP in rat liver cells [64]. The G protein, Gs, was purified and 
shown to be a heterotrimeric structure, composed of a α, β, and γ subunit [65, 
66]. Each of these subunits are comprised of 17 α subunits, 5 β subunits, and 12 
γ subunits [5]. The α subunit is GDP-bound and forms a complex with one β 
subunit and one γ subunit, which functionally dissociate from the βγ complex 
when it binds GTP. Mostly the α subunit is the active form when it is bound to 
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GTP and regulates the activity of downstream effectors [15]. Commonly, G 
proteins are designated by their α subunit, which means the Gs heterotrimeric 
complex includes Gαs; Gq includes Gαq; Gi includes Gαi; and so on.  The four 
major α subunit subfamilies are Gαs, Gαi, Gαq, and Gα12. Gαs is activated by a 
large group of GPCRs and stimulates adenylyl cyclase, which induces the 
synthesis of cyclic AMP from ATP. In contrast to Gs, Gαi inhibits adenylyl cyclase 
actitivity. Gαq activates phospholipase Cβ and Gα12 activates Rho-Guanine-
Nucleotide Exchange Factors (GEFs) [5, 67] (Figure 2). Pertussis toxin (PTX) 
was the first tool for characterizing G-protein-dependent signaling processes.  
PTX specifically inactivates all members of the Gαi family of G proteins (Gαi1, 
Gαi2, Gαi3, GαoA, GαoB, Gαt1, Gαt2 and Gαz). All other G proteins are insensitive to 
PTX [67]. PTX catalyses the ADP-ribosylation of a conserved arginine residue 
(Arg-178 in Gαi1, Arg-201 in Gαs and Arg-174 in Gαt) on Gα proteins resulting in 
inhibition of both GTPase activity and its interaction with Gβγ (Table 3) [68-70].  
In addition to Gα subunits, the Gβγ dimer itself also has an ability to 
induce signal transduction pathways modulating its own set of effectors, such as 
phospholipase Cβ, adenylyl cyclase, and K+ channels [71-76] (Table 3).  
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Figure 2. Classical overview of GPCR signal transduction pathways.  
Normally GDP are bounded in Gα subunit under the inactive state lacking ligand 
binding. Ligand binding to the GPCR induces GPCR activation, which causes 
GDP exchange with GTP and dissociation between Gα and βγ subunit. In the 
case of the β2 adrenergic receptor, agonist binding leads to receptor activation 
that induces Gαs activation. This activation stimulates secondary effector, 
adenylyl cyclase, which induces accumulation of cyclic AMP. The accumulated 
cyclic AMP activates a serine/threonine kinase, protein kinase A (PKA) 
activation. PKA activation leads to phosphorylation of various kinases and 
transcriptional factors. The βγ subunit modulates α subunit independent 
pathways. 
Adapted from Pierce et al [67]. 
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The β and γ subunits form a functional unit that only can be dissociated under 
denaturing conditions. Even though most β subunits can interact with most γ 
subunits, not all possible combination of subunits have been identified [4, 77]. β 
and γ proteins are found in a wide variety of cell types except 1 Gβ and 5 Gγ 
proteins, which are expressed in selective tissues, such as the brain or taste 
buds (Table 2).  Therefore, overlapping signaling cascades through Gβγ can also 
increase the complexity of intracellular signaling. To terminate the signal, 
hydrolysis of GTP to GDP is controlled by the regulator of G protein signaling 
(RGS) protein leading to reassociation of the heterotrimer and the termination of 
the activation cycle. The extraordinary combinational complexity of αβγ 
heterotrimers limits the ability to identify signal transduction pathways induced by 
G proteins, in spite of technological advances [67]. 
In addition to the classical G protein signaling pathways an additional layer 
of complexity has been added to models of GPCR activation.  For example, β2AR 
shows coupling to both Gαs and Gαi in cardiac myocytes [78] but can also induce 
a signal transduction cascade through MAP kinase pathways, which is mediated 
in a G protein-independent manner through β-arrestins [79, 80].  Because of the 
complexity of theses pathways, specific G protein subunit pairs that function on 
specific signal transduction pathways have rarely been shown.  
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Constitutively Active Mutant GPCRs 
 Ligand-independent GPCR activation that leads to G-protein activation is 
called constitutive activity [81]. Since the first constitutively active mutants (CAMs) 
were identified in α1-adrenergic receptor in 1990 [82], CAMs have been identified 
in almost all classes of GPCRs and are not limited to specific secondary 
messengers. Because unstimulated wild type GPCRs have differential basal 
activity from fully inactive to completely active, the exact definition of a CAM 
remains controversial [83]. The general definition of a CAM is is a receptor that 
has an increase in basal activity compared to its wild type counterpart without 
stimulation [81, 83]. 
 GPCR activation requires an alteration of the wild type conformation in 
order to trigger G protein activation. This activation also induces the activation of 
other protein involved in signal transduction and receptor trafficking.  These 
include protein kinase A (PKA) and protein kinase C (PKC), or a family of G-
protein-coupled receptor kinases (GRKs). Generally GPCR activity is down-
regulated with GRK and β-arrestins. In fact, GRK phosphorylation induces 
binding of arrestin proteins to the receptor and inhibits further interactions 
between the receptor and the G protein [84-86]. CAM GPCRs mimic, to some 
degree, the active conformation of the wild type receptor and spontaneously 
adopt a structure that is able to activate G proteins [81]. Therefore, the position 
and characteristics of the CAMs potentially provides a snapshot of the structural 
differences between the inactive and the active states of GPCRs.  
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 Kjelsberge et al [87] suggested the loss of intramolecular interactions 
induces a gain-of function CAM phenotype implying the existence of structural 
constraints that maintain the silence of a ligand-free receptor. They described a 
mutation of Ala293 to any other of the 19 amino acids in the α1B-adrenergic 
receptor resulted in constitutive activation [87]. Interestingly, a number of GPCRs 
in family A have been characterized by the conserved motif, D/ERY, at the 
junction of third TM domain and intracellular loop as the main structural 
constraint for maintaining the receptor inactivation. Mutation of the first residue of 
this motif in rhodopsin [88], α1B-adrenergic receptor [89], β2-adrenergic receptor 
[90], gonadotropin-releasing hormone receptor [91] M1 muscarinic receptor [92], 
CXC chemokine receptor 2 (CXCR2) [93] or the lutropin/choriogonadotropin 
receptor [94] leads to constitutive activation. Two models possibly explain the 
constitutive activity in these mutants. One model suggests that the mutation 
might disrupt the constraining interactions of the arginine residues in TM1, 2, and 
7 [87, 89, 95].  However another model that is broadly accepted has constitutive 
activity mediated through the disruption of an ionic interaction between the 
arginine and the aspartic or glutamic acid of the motif [2, 91, 96]. Alternatively, 
the D/ERY motif might regulate the active state the CAMs using other 
mechanisms.  
 Other domains have been shown to be important for GPCR activation as 
well.  One example is the large ectodomain of the luteinizing hormone receptor 
[97] or thyroid stimulating hormone receptor [81].  This region constrains the TM 
region maintaining the inactive state and its deletion leads to constitutive 
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activation. In addition the long C-terminal intracellular domain (more than 350 
residues) of the metabotropic glutamate receptor 1 constrains G protein 
activation.  A number of splice variants of the C-terminal domain induce 
constitutive activity [98]. Interestingly, no CAMs of GPCRs encoding a mutation 
on N-terminus have been reported except CAM of thyloid stimulating hormone 
receptor (TSHR) that present a mutation in large N-terminal exodomain [99, 100]. 
 
Constitutively Active Mutant Viral GPCRs 
Given the flexibility of GPCR signaling and its promiscuous contribution to 
different physiological processes, it seems obvious that viruses would have 
evolved proteins to exploit these receptors for their evolutionary advantage. 
These pirated receptors could function to aid in recognition and infection of 
permissive cells or for activating host signaling in order to evade immune 
recognition or aid in replication [101].  
Many DNA-viruses, such as Kaposi sarcoma-associated herpesvirus 
(KSHV), Epstein–Barr virus (EBV), human cytomegalovirus (HCMV), and human 
herpesvirus 6 and 7 encode GPCRs that have been hijacked from their cellular 
hosts and rendered constitutively active following mutations in key structural 
motifs. Several CAM GPCRs have recently been implicated in virally-induced 
oncogenesis [102]. One example is KSHV, the causative agent of Kaposi’s 
sarcoma (KS) [103] and primary effusion lymphoma [104]. The KSHV genome 
encodes a GPCR, ORF74, whose closest homologues are the chemokine 
receptors CXCR1 and CXCR2 [105]. KSHV ORF74 binds a variety of 
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chemokines, such as CXCL-1, 2, 3, 5, 7, 8, 10 and 12 [106]. Chemokines, such 
as CXCL-1 and CXCL-8, can further activate ORF74 or function as neutral 
ligands [107].   Others, such as CXCL-10 and CXCL-12, can inhibit ORF74  
signaling functioning as inverse agonists [108]. In addition, KSHV ORF74 
induces cellular transformation in NIH3T3 cells and tumorigenesis in nude mice 
[109]. Furthermore, transgenic mice expressing KSHV-ORF74 develop 
angioproliferative lesions in multiple organs, which is morphologically identical 
with KS [110]. These tumors are highly vascularized, contain a spindle cell 
component, express VEGF-C mRNA, and many of the cells are CD31+ cells. 
CD31 and VEGF-C expression are typically displayed in KS [111]. 
KSHV ORF74 signals through Gq based on the accumulation of inositol 
phosphate from the activation of phospholipase C.  In addition KSHV ORF74 is 
not inhibited by PTX treatment whereas chemokine receptors couple to Gi [112]. 
KSHV ORF74 stimulates PI3K–AKT/Protein Kinase B (PKB) pathway in 
endothelial cells, which protects them from apoptosis [113]. Therefore, the 
survival of KSHV-infected endothelial cells would allow for longer survival and 
production of the virus. Stimulation of AKT/PKB in KSHV-ORF74-expressing 
cells is dependent on βγ subunits of the G protein in both PTX-sensitive and -
insensitive G proteins [93, 105]. In addition to G-protein mediated signaling, G-
protein independent signal transduction was reported. Burger et al showed that 
KSHV-ORF74 constitutively induces the activation of the JAK-STAT3 pathway 
[114] (Figure 3). 
	   20	  
Figure 3. KSHV-ORF74 induced signal transduction pathways mediated by 
both Gαi and Gαq. 
G-proteins, Gαi and Gαq, drive PI3K (red arrow) and PLC-β (blue arrow) 
dependent intracellular cascades, respectively. In addition Gβγ also induces 
PI3K mediated signaling. G-protein independent kinase (orange dotted arrow), 
and JAK-STAT3 (orange arrow), are also induced by ORF74. KSHV ORF74 
ligand-independently activates various transcriptional factors. Abbreviations: PLC 
(Phospholipase C), PKC (Protein kinase C), MEK (Mitogen activated protein 
kinase kinase), MAPK (Mitogen activated protein kinase), PI3K 
(Phosphatidylinositol 3-kinases), PKB (Protein kinase B), JAK (Janus activated 
kinase), STAT3 (Signal transducers and activators of transcription protein), AP-
1(Activator protein-1), CREB (cyclic-AMP-response-element-binding-protein), 
NFAT (Nuclear factor activator of T cells), HIF-1α (Hypoxia-inducible factor-1α). 
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GPCRs in Cancer 
Experimental and clinical evidence indicates that GPCRs have a critical 
role in cancer progression and metastasis. However these mechanisms cannot 
completely explain all origins of cancer. Recently it has been suggested that 
malignant cells hijack the normal physiological function of GPCRs leading to 
autonomous proliferation, immune evasion, increased nutrient and oxygen 
supplies, invasion of the surrounding tissues, and dissemination to other organs 
[19].  Cancer cells will often overexpress GPCRs and their subsequent 
stimulation via autocrine or paracrine agonists released by tumor or stromal cells 
stimulate GPCRs and their signal transduction pathways. In fact, many GPCRs 
are overexpressed in different cancers (Table 4) and contribute to tumor cell 
proliferation mediated through autocrine and paracrine activation. For instance, 
the activation of chemokine receptors such as CXCR2 after stimulation with 
interleukin-8 (IL-8, also known as CXCL8) and GRO-α (also known as CXCL1 
and melanoma growth stimulatory activity α) from tumor cells contributes   
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Table 4. GPCRs in cancers. 
GPCRs and their cognate ligand interaction contribute to tumor growth, survival, 
metastasis, invasion and/or angiogenesis.  
Abbrevivation: AT (angiotensin receptor), β1AR and β2AR (β1- and β2- 
adrenergic receptors), CCK (cholecystokinin), ETA (endothelin receptor type A), 
ETB (endothelin receptor type B), GPR30 (G protein- coupled receptor 30), 
GRPR (gastrin-releasing peptide receptor), IL8 (interleukin 8) LPA 
(lysophosphatidic acid), MC1R (melanocortin 1 receptor), MSH (melanocortin 1), 
NMBR (neuromedin B receptor), PAR-1(ptotease-activated receptor-1), PGE2 
(prostaglandin E2), SDF1 (stromal cellderived factor 1).  
Modified from Dorsam and Gutkind [19]. 




Continued on the next page 
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to the progression of some tumors, such as squamous carcinomas of the head 
and neck (HNSCC) and melanoma [115, 116]. GPCRs are also considered key 
mediators of inflammation, thus providing a possible connection between chronic 
inflammation and cancer.  Inflammation is considered an important component in 
tumorigenesis and offers novel therapeutic targets [117-119]. Furthermore 
GPCRs, especially chemokine receptors, play a central role in tumor-induced 
angiogenesis and could induce GPCR-guided migration of cancer cells to other 
organs.  Cancer cells manipulate GPCR signaling to attract endothelial cells and 
lead them to invade the tumor mass, thereby forming new vessels to provide 
nutrients and oxygen. Therefore, distracting or inhibiting GPCRs and their 
downstream targets might provide an opportunity for the development of novel 
mechanism-based strategies for cancer diagnosis, prevention, and treatment [19]. 
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CHAPTER 2. CHEMOKINES AND CHEMOKINE RECEPTORS 
 
An Overview 
Initially chemokines were defined in 1989 as novel cytokines activating 
neutrophils [120]. They consist of a superfamily of proinflammatory mediators 
that promote the recruitment of leukocytes, and other cell types through GPCRs 
[121-123].  Chemokines contain a heparin-binding domain in the C-terminus that 
is responsible for binding to proteoglycans in the extracellular matrix [124]. 
Chemokines have been classified into 4 subfamilies, based on the spacing of the 
cysteines in the amino terminus: CXC, CC, CX3C and C [125]. Among 
chemokine subfamilies, CXC chemokines are further classified into Glu-Leu-Arg 
(ELR)+ and ELR− CXC chemokines, based on the presence or absence of the 
ELR motif in the N-terminus. IL-8, epithelial neutrophil activating protein (ENA 
also known as CXCL5), granulocyte chemotactic peptide-2 (GCP-2 also known 
as CXCL6), neutrophilic activating protein (NAP also known as CXCL7), 
melanoma growth stimulatory activities (MGSA (or GRO) α, β and γ also known 
as CXCL1, CXCL2 and CXCL3) belong to the ELR+ CXC subfamily [125].  
The ELR motif in the N-terminus of CXC chemokines modulates their 
specificity for binding to their cognate receptors. For example, ELR+ CXC   





Figure 4. Chemokine superfamily and their cognate chemokine receptors. 
Chemokines are classified based on the location of the highly conserved cysteine 
residues (orange round) in the N-terminus. There are four families, such as C, 
CC, CXC and CX3C chemokines. “x (blue round)” represents any amino acid 
between cysteine residues. Each chemokine interacts with their chemokine 
receptors expressed on a variety of cell types including leukocytes, epithelial and 
endothelial. 
Adapted from Sodhi et al [102]. 
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chemokines in the N-terminus of the molecule that immediately precedes the first 
cysteine are potent promoters of angiogenesis [126, 127]. By contrast, ELR- 
CXC chemokines, such as platelet factor-4 (PF-4) and interferon gamma-
inducible protein-10 (IP-10), are potent inhibitors of angiogenesis [128]. The 
structural dissimilarity in the N-terminus of these CXC chemokines plays an 
important role in receptor specificity. Based on the unique functional differences 
of the CXC chemokines, there has been increasing interest in their ability to 
regulate angiogenesis in cancer [124]. 
The function of the chemokine is initiated upon binding to their chemokine 
receptors, a member of the GPCR family [122]. Initially two specific chemokine 
receptors for IL-8, CXCR1 and CXCR2, were identified on the cell surface [129, 
130]. Since then, 18 functional chemokine receptors have been identified [131]. 
In addition there are two ‘decoy’ or ‘scavenger’ receptors, DARC and D6, which 
are known to bind several chemokines but do not induce signaling. It has been 
speculated that their function may be to modulate inflammatory responses 
through their ability to remove chemokine ligands from inflammatory sites [131].  
There are a number of common characteristics of chemokine receptors. 
All chemokine receptors identified so far are membrane-bound proteins 
composed of an N-terminus, 7-transmembrane domains, 3-extracellular and 
intracellular loops and a C-terminus, and can couple to G-proteins. The 
chemokine receptor is comprised of approximately 350 amino acids. The N-
terminus of the receptor is relatively shorter than other GPCRs and contains 
many acidic residues and N-linked glycosylation sites. An intracellular C-terminus 
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contains serine and threonine residues that act as phosphorylation sites for 
receptor regulation.  Also, a disulfide bond links highly conserved cysteines in 
extracellular loops 1 and 2 [132]. 
 Chemokine receptor 4, CXCR4, has drawn a lot of attention recently 
because it is a co-receptor for human immunodeficiency virus (HIV) [133] and its 
involvement in tumor progression and metastasis [134, 135]. CXCR4 was 
originally cloned as an orphan chemokine receptor, which is expressed on 
neutrophils, myeloid cells, and T lymphocytes [136]. Two years later CXCR4 was 
identified as a cofactor for T-tropic HIV-1 and HIV-2 envelope-mediated fusion 
and entry into CD4+ T cells [133]. The ELR- CXC chemokine, stromal cell-
derived factor (SDF-1α (also known as CXCL12)) is the only host ligand for 
CXCR4 and is a highly effective lymphocyte chemoattractant. It interferes with 
HIV-1 infection of permissive CD4+ cells in accordance with CXCR4 expression 
patterns [137, 138]. Stimulation with IL-4 induces an increase in cell-surface 
expression of CXCR4 on resting peripheral and cord blood T cells, whereas 
stimulation with CD28 or CD3 and CD2 lead to down-regulation of CXCR4 
expression [139]. CXCR4 knockout mice exhibit impaired B lymphopoiesis, 
myelopoiesis, hematopoiesis, derailed cerebellar neuron migration, and defective 
vascularization of the gastrointestinal tract [140-142] illustrating its role in a 
variety of developmental processes. CXCR4 is abnormally expressed on a 
variety of tumor cells, such as breast, head and neck, small-cell lung cancer 
(SCLC) and non-small-cell lung cancer (NSCLC).  CXCR4 stimulation is believed 
to play an important role in tumor cell proliferation, survival, angiogenesis and 
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migration [19]. Interestingly metastatic tumor cells express higher levels of 
CXCR4 than primary tumors in SCLC, NSCLC, neuroblastoma, melanoma, 
HNSCC, colorectal, thyroid, prostate, ovarian and renal-cell cancers, as well as 
in multiple haematopoietic malignancies, including chronic lymphocytic 
leukaemia, multiple myeloma and acute leukaemia.  This circumstantial evidence 
implicates a central role for CXCR4 and SDF-1α in tumor progression and 
metastasis [19, 143, 144].  CXCR4 is the best example of the role that 
chemokine receptors play in tumor development and progression. 
 
CXCR2 Activation and Signaling 
Most chemokines stimulate more than one chemokine receptor and many 
chemokine receptors are functionally activated by a number of chemokines [125]. 
IL-8 activates CXCR1 and CXCR2. Both receptors are highly homologous (77%) 
[129, 130], with most of the divergence in the N-terminus (29%) and ECL2 (55%) 
regions [145]. CXCR1 selectively bind either IL-8 or GCP-2, whereas CXCR2 can 
interact with CXCL-1, 2, 3, 5, 6, 7 and 8 [123]. Activation of both receptors upon 
ligand binding induces phosphatidylinositol (PI) hydrolysis, intracellular Ca2+ 
mobilization, and chemotaxis.  All can be inhibited with PTX, indicating that the 
both receptors couple to Gαi in neutrophils where Gαi2 is very abundant [120, 
146]. A major difference between CXCR1 and CXCR2 is phospholipase D 
activation, which is mediated via CXCR1 activation, implicating that the two 
receptors have different cellular functions [147]. In addition to phospholipase D 
activation, receptor trafficking is a distinguishing characteristic between CXCR1 
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and CXCR2, which induces leukocyte activation and regulation in response to IL-
8 [148, 149]. Over 95% CXCR2 internalizes within 5 min of activation with IL-8 
compared with about 10% for CXCR1 [150, 151].  This implies that receptors are 
regulated differently upon stimulation and that they induce differential signaling. 
Initially CXCR2 was cloned in 1991 from human promyelocytic leukemia 
cells, HL60s [129]. CXCR2 is expressed on various cell types and tissues 
including neutrophils, monocytes, eosinophils, mast cells, basophils, lymphocytes, 
epithelial cells, endothelial cells, smooth muscle and cells of the central nervous 
system [152]. Treatment of CXCR2 expressing cell lines with PTX completely 
disrupted IL-8 mediated inhibition of forskolin-stimulated cyclic AMP 
accumulation indicating that CXCR2 activation induces Gαi dependent signal 
transduction pathways [153]. This Gαi dependent signaling stimulates the 
accumulation of intracellular inositol phosphate and increases intracellular 
calcium. CXCR2 activation, followed by the initiation of G proteins including βγ 
subunit mediated signals, induces important downstream regulators of 
intracellular signaling such as cAMP/protein kinase A (PKA), protein kinase C 
(PKC), phospholipase C (PLC), phosphoinositide 3-kinase 
(PI3Kinase)/AKT/mTOR, Ras/Raf/MEK/JNK/p38/ERK1/ERK2, and activates NF-
kB pathways.  These pathways subsequently induce proliferation, migration, and 
inhibition of apoptosis [154-157]. 
Initially, Burger et al [93] demonstrated a constitutively activate mutant 
CXCR2 could be generated with a single point mutation in the highly conserved 
DRY motif (D138V).  This residue was chosen based on KSHV ORF74. KSHV 
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ORF74 is constitutively active and induces tumorigenesis.  This receptor 
encodes a VRY motif instead of a DRY motif at the junction of the TM3 and ICL2. 
The CXCR2 mutant (D138V) induced cellular transformation in NIH3T3 cells that 
is comparable to KSHV ORF74. To evaluate G protein-coupled signaling through 
the PLC pathway, accumulation of inositol phosphate in NIH3T3 cells expressing 
D138V mutant was measured.   KSHV ORF74 and the CXCR2 (D138V) mutant 
increased the amount of inositol phosphate 3.5 and 3.0 fold higher than 
untransfected NIH3T3 cells.. PTX treatment did not completely inhibit the 
accumulation of inositol phosphate for both the KSHV ORF74 and the D138V 
mutant, which suggests that the D138V mutant induces an agonist-independent 
signal transduction pathway similar to the KSHV ORF74. In addition, both 
receptors showed only a small Ca2+ response upon IL-8 stimulation suggesting 
constitutive activity is independent of ligands. Constitutively active mutant 
CXCR2 (D138V) mediated cellular transformation was dependent on constitutive 
STAT3 phosphorylaton on Tyr705 as part of JAK2 activation [114].  This laid the 
foundation for our current studies of CAM CXCR2 and their role in cellular 
transformation. 
 
CXCR2 IN TUMORIGENESIS 
The role of CXCR2 mediated, ELR+ CXC chemokine-induced 
angiogenesis in vivo has been investigated using the corneal micropocket assay 
for angiogenesis. Interestingly CXCR2-/- mice or CXCR2+/+ mice treated with 
neutralizing antibodies (Abs) to CXCR2 interfered with ELR+ CXC chemokine-
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mediated angiogenesis [158]. This evidence demonstrated that CXCR2 is both 
essential and sufficient to mediate the angiogenic effects of ELR+ CXC 
chemokines.  Because of its role in angiogensis and the role that angiogensis 
plays in tumor formation, there has been an increasing focus on CXCR2 and its 
relationship to cancer.  Another in vivo model described a correlation between the 
expression of endogenous ELR+ CXC chemokines that induce tumor growth and 
the metastatic potential of Lewis lung cancer (LLC) tumors in CXCR2+/+ mice. 
The LLC primary tumors and spontaneous metastasis to the lungs were 
significantly reduced in CXCR2-/- mice. Morphometric analysis of the primary 
tumors in CXCR2-/- mice described areas with greater tumor-associated necrosis 
and reduced tumor-associated angiogenesis when compared with tumors grown 
in CXCR2+/+ mice. These findings were further confirmed in CXCR2+/+ mice 
treated with neutralizing Abs to CXCR2 [159]. This evidence supports the view 
that CXCR2 mediates the angiogenic activity of ELR+ CXC chemokines in a 
preclinical model of lung cancer. 
IL-8, activation of CXCR1 and CXCR2 induces mitogenic and angiogenic 
factors that contribute to human cancer progression [160]. Higher-grade human 
melanoma specimens and metastases express higher levels of CXCR2 
suggesting an association between the expression of IL-8 and CXCR2 [161]. 
Singh et al [162] demonstrated that CXCR1 or CXCR2 overexpressed in non-
tumorigenic and low-tumorigenic melanoma cells enhanced cellular proliferation, 
chemotaxis and invasiveness in vitro. Interestingly, CXCR1 or CXCR2 
overexpression in non-tumorigenic melanoma cells induces tumorigenicity as 
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examined in vivo [162].  In addition IL-8-induced and CXCR1- or CXCR2-
dependent melanoma cell proliferation and migration was mediated through the 
ERK1/2 MAP kinase pathway. However, the functional significance of these 
receptors, CXCR1 and CXCR2, in melanoma progression remains unclear [162].  
In human ovarian cancer cells, SK-OV-3, CXCR1 and CXCR2 are strongly 
expressed. IL-8 stimulation through p44/42 MAP (Erk1/2) kinase transformed 
ovarian cancer cells to have increased membrane ruffling and the 
formation/retraction of thin actin-like projections.  All of these phenotypes are  
indicators cancer cell metastasis [163].  
Overexpression of CXCL-1 and 2 (also known as GRO-α and β) and 
CXCR2 in esophageal squamous cell carcinoma tissues, WHCO1, 5 and 6, 
demonstrated an important role for CXCR2 activation in cellular proliferation. This 
proliferative autocrine loop between GRO α/β and CXCR2 indicated a critical role 
for CXCR2 in the development and maintenance of squamous esophageal 
cancer [164]. 
Heterotropic and orthotopic models of murine renal cell carcinoma using 
CXCR2-/- and CXCR2+/+ BALB/c mice demonstrated that CXCR2 induces tumor-
associated angiogenesis and tumor growth. In this murine model, CXCR2 ligand 
(CXCL-1, 3, 5 and 8) expression directly correlated with tumor growth in 
CXCR2+/+ mice. In contrast, a significant reduction in tumor growth in CXCR2-/- 
mice was observed and correlated with decreased angiogenesis and increased 
tumor necrosis [165].  
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Human prostate cancer biopsy tissue analysis showed a progressive 
increase in IL-8 expression in the early stages (Gleason 3 or 4) compared with 
normal prostate epithelium [166]. Elevated IL-8 expression was also detected in 
the serum of prostate cancer patients. There was a 2-5 fold higher elevation of 
IL-8 in patients with prostate cancer compared with normal or benign prostatic 
hypertrophy patients [167]. In addition, the localization of IL-8 and CXCR1 and 2 
expression to the cytoplasm and the basal membrane of prostate cancer cells 
was even more distinct in the transurethral resection of the prostate biopsy 
samples of advanced and androgen-independent disease (Gleason pattern 5) 
[166]. The androgen-independent prostate cancer cell line, PC3, exhibited high 
IL-8 expression and activation of its receptors, CXCR1 and CXCR2, which 
promoted tumorigenicity of the cells [166]. 
The human pancreatic cancer cell line, Capan-1, had increased IL-8 and 
CXCL-1 expression, and these chemokines induced mitogenic effects through 
CXCR1 and CXCR2 in vitro [168]. Additionally CXCR2 inhibition completely 
abolished neovascularization in the human pancreatic cancer cell line, BxPC-3 
[169]. 
The highly metastatic colon cancer cell line, KM12L4, expressed higher 
levels of IL-8 and cognate receptors, CXCR1 and CXCR2, than the low 
metastatic cell line, KM12C, and non-metastatic cell line, Caco2. Also IL-8 
stimulation induced higher cellular proliferation for Caco2 than KM12C and 
KM12L4 cell lines respectively. Inhibition of IL-8, CXCR1, or CXCR2 reduced 
cellular proliferation in both KM12C and KM12L4 cells. Moreover, the expression 
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level of IL-8 was directly involved in the migratory potential of colon cancer cell 
[170]. These data suggest that IL-8 and its receptors potentially modulate human 
colon cancer tumorigenesis. 
Taken together, CXCR2 activation induced by its ligands is a contributing 
factor to tumor-associated angiogenesis, tumorigenesis and metastasis. 
Development of novel agents targeting multiple angiogenic mediators is currently 
in progress [171, 172]. Among those targets, CXCR2 is one of the best 
candidates for anti-angiogenic therapies in that it is the universal receptor for all 
angiogenic CXC chemokines. Therefore targeting CXCR2 along with other 
angiogenic factors is a promising strategy to overcome tumorigenesis and 
metastases in a variety of cancers [159, 165]. 
 
Summary and Statement of Research Aims 
The metastatic potential of primary tumors correlates with tumor 
proliferation and the level of tumor-related angiogenesis [165, 173]. In fact, solid 
tumors lacking a vascular conduit cannot grow more than several cubic 
millimeters, because nutrients and gas exchange cannot occur [165, 173]. 
Evidence suggests that the function of CXCR2 in tumor formation, proliferation 
and metastasis is associated with its expression and activation in endothelial 
cells. CXCR2-induced neovascularization promotes tumor cell proliferation 
providing tumor cell access to the vasculature [159, 165]. Based on this 
information, CXCR2 is an attractive target for inhibiting tumor-related 
angiogenesis. CXCR2 binds to all angiogenic ELR+ CXC chemokines and the 
	   38	  
inhibition of CXCR2 results in the lack of angiogenic activity in vivo. Many studies 
show that CXCR2 inhibition promotes a significant decrease in tumor size and an 
increase in tumor necrosis in vitro and in vivo [159, 165]. 
 
The main focus of this dissertation is not only the role of constitutive 
activation of CXCR2 followed in cellular transformation, but also the mapping of 
intracellular signal transduction pathways mediated by constitutive activation. 
The hypothesis of this dissertation is that the CAM CXCR2 induced by an N-
terminal single point mutation promotes tumor development. To investigate this 
hypothesis, the following research objectives were performed:   
1. Screening and identification of CXCR2 CAMs using the yeast model 
system 
2. Verification of tumorigenicity mediated by CXCR2 CAMs in vitro and in 
vivo. 
3. Identification of an intracellular signal transduction cascades induced by 
CXCR2 CAMs. 
 






PART II. SCREENING FOR NOVEL CONSTITUTIVELY 
ACTIVE CXCR2 MUTANTS AND THEIR CELLULAR 
EFFECTS 
In Press as “Screening for Novel Constitutively Active CXCR2 Mutants and 
their Cellular Effects” Methods in Enzymology: Constitutive Activity and 
Inverse Agonism, Giljun Park, Tom Masi, Chang K. Choi, Heejung Kim, Jeffrey 
M. Becker, and Tim E. Sparer 
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CHAPTER 1.  ABSTRACT 
 
Chemokines play an important role in inflammatory, developmental, and 
homeostatic processes. Deregulation of this system results in various diseases 
including tumorigenesis and cancer metastasis. Deregulation can occur when 
constitutively active mutant (CAM) chemokine receptors, which are locked in the 
“on” position. This can lead to cellular transformation/tumorigenesis. 
The CXC chemokine receptor 2 (CXCR2) that has homology with CAM 
receptor, ORF74 is a G-protein-coupled receptor (GPCR) expressed on 
neutrophils, some monocytes, endothelial cells, and some epithelial cells. 
CXCR2 activation with ELR+ CXC chemokines induces leukocyte migration, 
trafficking, leukocyte degranulation, cell differentiation, and chemokine mediated 
angiogenesis. Activation of CXCR2 can lead to cellular transformation. We 
hypothesized that CAM CXCR2s may play a role in cancer development. In order 
to identify CXCR2 CAMs, mutant CXCR2s were screened using a modified 
Saccharomyces cerevisiae high-throughput system. Saccharomyces cerevisiae 
has been successfully used to identify GPCR and G-proteins interactions and 
autocrine selection for peptide agonists. The CXCR2 CAMs identified from this 
screen were characterized in the mammalian system. Their ability to transform 
cells in vitro was shown using foci formation, soft-agar growth, impedence 
measurement assays and in vivo tumor growth following hind flank inoculation. 
Signaling pathways contributing to cellular transformation were identified using 
luciferase reporter assays.  Studying constitutively active GPCRs is an approach 
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for “capturing” a pluridimensional GPCRs in a “locked” activation state. In order 
to address the residues necessary for CXCR2 activation, we used 
Saccharomyces cerevisiae for screening novel CAMs and characterized them in 
mammalian reporter assays. 
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CHAPTER 2.  INTRODUCTION 
 
Although there are many contributing factors to tumorigenesis, 
chemokines and their receptors can contribute to tumorigenesis and metastasis 
[134]. Chemokines function normally as small chemoattractant cytokines that are 
involved in inflammatory, developmental, and homeostatic processes [174]. 
Deregulation of this system is associated with the development of cancers and 
metastasis. One example of disruption of the chemokine pathway is the 
constitutively active mutant (CAM) receptors [134, 175].  These CAMs cause an 
alteration of the structural constraints, locking it into an active conformation. This 
conformational change induces ligand independent activation called constitutive 
activity [176]. CAM GPCRs are associated with the development of a variety of 
human diseases [177]. The best example of a constitutively active chemokine 
receptor causing cancers is the Kaposi sarcoma herpesvirus chemokine 
receptor, ORF74, which is a homolog for human CXCR2 [108].  This receptor 
has a ‘VRY’ motif instead of a ‘DRY’ motif between third transmembrane domain 
and second intracellular loop and has been shown to be constitutively active.  
Stable lines of NIH3T3 fibroblasts expressing ORF74 lead to cellular 
transformation [93, 106, 178]. These transfectants are tumorigenic in nude 
mouse and a transgenic mouse expressing ORF74 developed tumors resembling 
Kaposi’s sarcoma (KS) lesions [111]. 
CXC chemokine receptor 2 (CXCR2) is a G-protein-coupled receptor 
(GPCR) [179] and expressed on neutrophils, some monocytes, endothelial cells, 
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and some epithelial cells [180]. Activation of CXCR2 with ELR+ CXC chemokines 
leads to leukocyte migration, trafficking, leukocyte degranulation, cell 
differentiation, and ELR+ CXC chemokine mediated angiogenesis [123] [181]. 
Utilizing the induction of the natural pheromone response pathway, 
Saccharomyces cerevisiae has been successfully used to identify GPCR/G-
proteins interactions and selection of peptide agonists [182-185]. Recently 
allosteric peptide agonists for CXCR4 were identified using this system.  The 
pheromone responsive pathway was modified to include a hybrid G-protein to 
interact with CXCR4, elimination of growth arrest genes, and an auxotrophic 
marker under the control of the pheromone responsive element. With these 
modifications a library of CXCR4 ligands was screened to identify novel agonists 
[186].  
 To identify CXCR2 CAMs, the open reading frame (ORF) of CXCR2 was 
randomly mutated and expressed in this genetically engineered yeast. Using a 
simple selection for growth on media lacking histidine we identified novel CXCR2 
CAMs. Constitutive activation was confirmed with induction of beta-
galactosidase, which was under the control of the pheromone responsive 
element. In order to characterize the CXCR2 CAMs in the mammalian system 
and to link them to cellular transformation, the first step in tumorigenesis, we 
generated stable transfectants using CXCR2 CAMs and measured foci 
formation, anchorage-independent growth in soft agar, impedance, and tumor 
formation in vivo. To address the downstream constitutively active signal 
transduction pathways immunoblotting and flowcytometry were used to identify 
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specific phosporylated signaling pathways.  Luciferase reporter constructs with 
CREB, STAT3, and NF-kB responsive elements can be used to identify important 
signaling pathways that could contribute to cellular transformation. Here we 
describe detailed approaches for successful identification and cellular 
characterization of CXCR2 CAMs. 
	   45	  
CHAPTER 3.  MATERIALS AND MATHODS 
 
Strains, media, and plasmids 
 Yeast strain CY1141 (MATα FUS1p-HIS3 can1 far1*1442 gpa1 (41)-
G@ai2 his3 leu2 lys2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3) contains  an 
integrated copy of a hybrid Gα subunit (GPA1(41)Gαi2) in which the N-terminal 33 
residues of human Gαi2 are substituted with the 41 N-terminal residues of GPA1 
[185].  For strain CY12946 (MAT2 FUS1p-HIS3 GPA1G@ai2(5) can1 far1*1442 
his3 leu2 lys2 sst2*2 ste14::trp1::LYS2 ste3*1156 tbt1-1 trp1 ura3) also contains 
a chimeric G protein GPA1Gαi2(5) in which the 5 residues of C-terminal GPA1 
were replaced with the C-terminal 5 residues of human Gαi2 [187]. In addition S. 
cerevisiae strain, BJS21 (MATa, prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52 
ste2::KanR) was used as a control to see the receptor expression on the plasma 
membrane. 
 Yeast expression vector, p426GPD (ATCC, #87361), was used to clone 
wild type and mutated human CXCR2. To estimated basal activity of receptor 
pMD1325 (a gift from Dr. Dumont, University of Rochester, School of Medicine 
and Dentistry) were transformed into yeast.  
 YPD is a basic enriched media to culture BJS21, CY1141 and CY12946, 
which contains 1% of BactoYeast extract (Difco), 2% of BactoPeptone (Difco), 
and 2% dextrose. For selective medium MLU (medium lacking uracil) contains 1x 
Yeast Nitrogen Base (YNB) without amino acids plus ammonium sulfate (Difco), 
2% glucose, 1% casamino acids (Difco). When also selecting for histidine and/or 
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leucine in combination with uracil the casamino acids is not added due to it 
containing both histidine and leucine. 
 
Cell lines, growth medium, mouse strain and plasmids 
 NIH3T3 (ATCC) and HEK293 (ATCC) were maintained in the medium 
containing DMEM with 10% bovine calf serum (Hyclone). 6 to 8 week old athymic 
nu/nu mice (Jackson Laboratory) were used for in vivo tumogigenesis assay. 
pcDNA3.1 (Invitrgen) and pcDNA3.1+GFP plasmids were used to clone wild type 
and mutants CXCR2 into mammalian cell line. Lipofectamine 2000TM (Invitrogen) 
was used for transfection. Neomycin (G418 Sulfate, Cellgro) was applied to 
select single clonal population. 
 
Reagents for Yeast transformation 
  1.0 M lithium acetate (LiAc) and 50% (w/v) polyethylene glycol (PEG) 
3350 are sterilized with 0.2 and 0.45 µm pore size filtration respectively and 
stored at room temperature. Single strand DNA (ssDNA, salmon sperm DNA, 
Sigma-Aldrich) is boiled for 10 min, cooled down on ice, and frozen at -20 
degrees Celsius. 
 
Reagents for Yeast Immunofluorescence 
  Potassium phosphate (KPi, 0.1 M, pH 6.5), SHA (1 M Sorbitol, 0.1 M 
NaHepes (pH 7.5), 5 mM NaN3), 4% formaldehyde, β-mercaptoethanol, and 
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yeast cell wall lytic enzyme (Fisher, Cat.No. BP2683-25). WT buffer: 1% fat free 
dry milk, 0.5 mg/ml BSA, 150 mM NaCl, 50 mM HEPES (pH 7.5), 0.1% Tween 
20, and 1 mM NaN3.  For anti-CXCR2 immunoblotting an antibody specific for 
human CXCR2 (sc-7304, SantaCruz Biotechnology) is used. HRP-conjugated 
secondary Ab was applied, and then detected with enhanced 
chemiluminescence system (ECL, Amersham). Hoechst dye (1 µg/ml, Molecular 
Probe) for nuclear staining is used to identify individual cells. 
 
Reagents for Subcellular fractionation 
 Sorbitol buffer (10 mM Tris (pH 7.6), 0.8 M sorbitol, 10 mM NaN3, 10 mM 
KF, 1 mM EDTA, pH 8.0), and sucrose buffer (10 mM Tris (pH 7.6), 1 mM EDTA, 
10% [w/v] sucrose) were used. 
 
Reagents for Immunoblotting 
 NuPAGE 12% Bis-Tris SDS-polyacrylamide gel (Invitrogen) and PVDF 
membrane (Invitrogen) were used. Primary antibodies: anti-FLAG M2 antibody 
(Eastman Kodak Co.) and anti-human CXCR2 (sc-7304-SantaCruz 
Biotechnology), and secondary antibody: anti-mouse HRP-conjugated secondary 
Ab (eBioscience) were applied.  Blocking media (1% dried milk in PBS/0.1% 
Tween 20) and wash media (PBS/0.1% Tween 20) were prepared.  ECL 
development kit (Amersham) and 2x SDS Sample Buffer (Invitrogen) were 
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applied. PE-conjugated human CXCR2 specific antibody (R&D Systems, 
FAB331P) for FACs anaysis was applied. 
 
Reagents for error-prone PCR 
 Primers forward and reverse for the CXCR2 ORF were synthesized to 
include unique restriction sites (Forward with HindIII 5’-
CCCAAGCTTATGGAAGATTTTAACATGGAGAGTG-3’ and Reverse with XbaI 
5’-GCTCTAGATTAGAGAGTAGTGGAAGTGTGC-3’). Low fidelity Taq polyerase 
(Fisher BioReagents) is preferred for error-prone PCR than high fidelity Taq 
polymerase. In addition dATP, dGTP, dTTP, dCTP, and manganese chloride 
were added separately to the reaction because they were modified in order to 
increase the error rate of the PCR reaction. 
 
Reagents for β-galactosidase assay 
 Basal activity of β-galactosidase was measured using a yeast β-
galactosidase assay kit (Pierce) according to the manufacturer's instruction.   The 
amount of β-galactosidase is expressed as Miller units. 
 
Yeast transformation  
 Maintain and culture yeast strains on YPD medium. Inoculate a fresh 
colony into 5 ml YPD and incubate with movement overnight at 30°C. Using the 
overnight culture inoculate 50 mls of YPD in a sterile flask to a final density of 
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5x106 cells/ml.  Incubate the culture as above until a cell concentration of 2x107 
(usually 3-5 hours) is achieved. Centrifuge the cells at 4,000 rpm for 5 minutes 
and discard the supernatant.  Wash the cells one time in 25 ml sterile water, 
centrifuge and then resuspend in 1 ml of 100 mM LiAc and transfer to a 1.5 ml 
microcentrifuge tube. Centrifuged the cells at top speed in a microcentrifuge for 
15 seconds and remove the LiAc. Resuspend the cells in 400 µl of 100 mM LiAc.  
For each plasmid to be transformed, aliquot 50ul of cells to a clean microfuge 
tube. Boil the ssDNA for 5 min, and keep on ice until needed. Centrifuge each 
aliquot of cells and the discard the supernatant. In the following order, carefully 
add each of the following reagents: 240 µl of 50% PEG, 36 µl of 1.0 M LiAc, 25 µl 
of ssDNA, 5 µl (0.1-10 µg) of cloned DNA (e.g. wild type CXCR2 cloned into 
p426 GPD) and 45 µl of sterile water. Vortex the mixture until cell pellet is 
completely resuspended (about 1-2 min). Include a negative control reaction 
without cloned DNA. Incubate the mixture at 30°C for 30 min and heat shock at 
42°C for 25 min. Centrfuge the heat shocked cells at top speed in a 
microcentrifuge for 2 min, and then remove the supernatant. Resuspend the cells 
in 1 ml of sterile water and plate 200 µl on selective media lacking uracil and 
incubate at 30°C. Transformed yeast colonies will be seen in 2-3 days. 
 
Yeast Immunofluorescence analysis 
 Fix 1×108 cultured yeast cells in 0.1 M KPi (pH 6.5) and 4% formaldehyde 
for at least 1 hr then centrifuge and resuspend again in fix (as above) for at least 
12 hrs but less than 24 hrs. After fixation, resuspend the cells in 5 ml of SHA (1 
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M Sorbitol, 0.1 M NaHepes, pH 7.5, 5 mM NaN3) and store at 4°C for up to 2 
weeks.  To remove the cell wall, incubate 500 µl of the resuspended cells in 1 ml 
of SHA, 0.2% of β-mercaptoethanol, and 10 mg/ml of yeast cell wall lytic enzyme 
(Fisher, BP2683-25) at 30°C for 1.5 hrs. After incubation, centrifuge the cells and 
resuspended in 1% SDS, wash with 1ml of SHA and resuspend with SHA (~100 
µl). After spinning down the cells, incubate the cells with a primary specific 
human CXCR2 antibody (sc-7304, SantaCruze Biotechnology) (1:100 dilution in 
WT buffer (1% fat free dry milk, 0.5 mg/ml of BSA, 150 mM of NaCl, 50 mM 
HEPES (pH 7.5), 0.1% Tween 20, and 1 mM NaN3)) overnight at 4ºC.  Wash the 
cells 5 times with WT buffer, and then add a FITC labeled anti-mouse secondary 
antibody (sc-2099, SantaCruz Biotechnology) (1:1,000 dilution in WT buffer). 
After incubation at room temperature for 30 min, wash the cells 5 times with WT 
buffer and stain with 100 µl of Hoechst dye (1 µg/ml, Molecular Probes). Wash 
the cells 3 times in sterile water and store at 4ºC in the dark. Take 
photomicrographs using an Olympus BX 50 microscope and photograph with 
Pictureframe version 2.3 (Olympus). 
 
Subcellular fractionation 
 Harvest 1×107 cells grown in selective medium lacking uracil, wash once 
with 1 ml sorbitol buffer (10 mM Tris, pH7.6, 0.8 M sorbitol, 10 mM NaN3, 10 mM 
KF, 1 mM EDTA, pH 8.0), centrifuge and remove supernatant. Wash again with 1 
ml sucrose buffer (10 mM Tris pH7.6, 1 mM EDTA, 10% [wt/vol] sucrose), and 
then resuspend the cells in 1 ml sucrose buffer containing protease inhibitors (10 
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µg/ml phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, and 2 µg/ml pepstatin A). 
Mechanically disrupt the cells with glass beads and centrifuge at 300xg for 5 min 
to remove any unlysed cells. Mix 0.5 ml of supernatant with 0.5 ml of 50 % 
(wt/vol) sucrose in 10 mM Tris (pH 7.6), 1 mM EDTA, and layer on top of a 4 ml 
of 30-60% linear sucrose gradient prepared in 10 mM Tris (pH 7.6) and 1 mM 
EDTA. For the gradient separation, overlay the cells on the sucrose cushion and 
centrifuge at 150,000×g for 20 hours. Collect fractions (≈250 µl) from bottom of 
the gradient by inserting a long blunt-end needle into the bottom of the tube.  
Make sure that the needle rests on the bottom of the ultracentrifuge tube. Dilute 
10 µl of each fraction 1:1 in 2x sample buffer. Warm samples for 10 min at 37ºC 
and then load on a NuPAGE 12 % Bis-Tris SDS-polyacrylamide gel (Invitrogen). 
Other gels can be substituted but this manufactured gel gave the best-looking gel 
for publication.  Transfer the proteins via wet transfer onto a PVDF membrane 
(Invitrogen).  After transfer, block the membrane in 1% non-fat dried milk in 
PBS/0.1% Tween 20. The yeast pheromone receptor, Ste2p-FLAG, which is 
expressed by the BJS21 strain, was used as a positive control for plasma 
membrane expression of the receptor. After blocking, probe the membrane for 
Ste2p-FLAG expression with an anti-FLAG M2 antibody (1:25,000 dilution, 
Eastman Kodak Co.) and human CXCR2 antibody (1:10,000 dilution, sc-7304, 
SantaCruz Biotechnology) together, which were incubated at 4ºC overnight.  
Make all dilutions in wash buffer.  Wash twice with PBS/0.1% Tween 20, then 
add the anti-mouse HRP-conjugated secondary Ab (1:10,000 dilution, 
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eBioscience) for 30min.   Wash blots 4x with PBS/0.1% Tween 20 and then 
detect with ECL (Amersham). 
 
Identification of CXCR2 CAMs in the yeast strains 
 CXCR2 CAMs were identified in the FUS1-HIS3 yeast strains when they 
grew on medium lacking uracil, histidine and in the presence of 3-amino-1,2,4-
triazole (3-AT), which is used to suppress endogenous HIS expression. The 
CAMs activate the chimeric G proteins resulting in activation of the pheromone 
response pathway and subsequent activation of the fus1 promoter upregulating 
the HIS auxotrophy gene. In order to confirm and quantify the degree of 
constitutive activation, a plasmid containing β-galactosidase (lacZ) under the 
control of the FUS1 promoter was transformed into these strains. The plasmid 
FUS1-lacZ (pMD1325) allows expression of lacZ after induction of the 
pheromone pathway. This plasmid also contains a LEU2 selectable marker for 
selecting transformants [188].  Once the transformants were created, the amount 
of β-galactosidase produced was quantified using a standard kit. 
 
Random mutagenesis 
 Perform random mutagenesis by using error-prone PCR [189]. Synthesize 
primers up and downstream of the CXCR2 ORF to include unique restriction 
sites for cloning into the expression vector (HindIII and XbaI).  Alter three 
parameters in order to increase the mutagenic potential of the PCR reaction. 
First, use low fidelity Taq polymerase (Fisher BioReagents).  Second, adjust the 
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final concentration of dTTP/dCTP to 0.8 mM while keeping the remaining 
nucleotides at 0.25 mM [190].  Alteration of the ratio of nucleotides increases the 
likelihood of misincorportions during the amplicon synthesis.  Finally, add 
manganese chloride to a final concentration of 500nM. Manganese chloride 
concentrations lower than 500 nM are less mutagenic. Digest the PCR products 
from random mutagenesis with HindIII and XbaI, and ligate into the p426GPD 
yeast expression vector by standard cloning procedures. Select yeast colonies 
(about 200) on media lacking uracil. Extract plasmid encoding the CXCR2 CAMs 
by using a yeast plasmid miniprep kit (ZymoprepTM, ZYMO RESEARCH). Then 
transform the extracted yeast plasmid E.coli (MAX Efficiency® DH5α™ Competent 
Cells, Invitrogen) in order to acquire enough DNA for sequencing. Purify the 
CXCR2 CAMs/p426GPD plasmid using a miniprep kit (Promega) and sequence 
using primers flanking the multiple cloning regions. 
 
β-galactosidase assay 
 Plasmid pMD1325 (gifted from Dr. Dumont) contains a FUS1-lacZ that is 
inducible by receptor activation [188]. β-galactosidase assay was performed as 
previously described [191]. Briefly, grow transformed yeast strains CY1141 
and/or CY12946 (with the p426GPD expressing CXCR2 CAMs and pMD1325) 
overnight in selective growth media at 30ºC until they reach 5×106 cells/ml. Wash 
with sterile water, and grow at 30ºC in selective media for one doubling based on 
a hemocytometer count, Measure basal activity of β-galactosidase using a yeast 
β-galactosidase assay kit (Pierce) according to the manufacturer's instructions. 
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This allowed the comparison of β-galactosidase production from yeast 
expressing the wild-type CXCR2 containing strains normalized to the activity of 
each mutant. 
 
Transfection of NIH3T3 cells to establish stable cell lines 
expressing CXCR2 CAMs 
 In a 6-well dish transfect 2 µg of DNA and 4 µl of lipofectamine 2000 
(Invitrogen) into 5x106 NIH3T3 cells. The transfection efficiency was optimized by 
varying DNA and lipofectamine concentrations with an indicator plasmid such as 
pcDNA3.1 expressing GFP.  About 24-48 post transfection, change the growth 
medium with medium supplemented with 0.8 g/L of G418 sulfate. Replace the 
medium with fresh selection media and wash with ice-cold PBS every 3 days for 
14-21 days. This is the period required for the selection of stably transfected 
NIH3T3 cells. Untransfected NIH3T3 cells will detach and will be washed away 
during the medium exchanges. Once all of the cells have died in the 
untransfected control, keep the growing cells in selective medium until colonies 
develop. Once colonies have formed, remove media from the plate and circle 
colonies with a colored pen on the bottom of the plate. Choose 5-10 colonies per 
construct to check for expression. Place a cloning disc (Scienceware) that has 
been soaked in trypsin-EDTA solution (Hyclone), over the top of the colony for 2-
3 minutes. Place the disc containing the stable clone into a well of a 24-well plate 
containing selection media. Change the media everyday until the cells have 
achieved 80-90% confluency. Trypsinize the confluent well of cells and transfer 
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to a 6-well dish and maintain in selection media until 80-90 % confluency. 
Expand the cells into a T-25 cell culture flask and analyze for CXCR2 expression.  
Verify the surface expression of the receptor for each of the clonal population by 
immunostaining followed by flow cytometery analysis using a FACs machine 
(Calibur, BD biosciences). Trypsinize 1×106 stably transfected cells, wash with 
ice-cold PBS and then block with 1% goat serum in PBS. Incubate cells with a 
PE-conjugated human CXCR2 specific antibody (R&D Systems, FAB331P) for 
30 min at room temperature.  Wash cells once with PBS and fix with 4% 
paraformaldehyde and analyze by flowcytometry.  After verifying expression, 
expand cells and store in 10% DMSO in media in the freezer (-140 ºC) (liquid 
nitrogen is adequate) until further analysis.  This is step is important as NIH3T3 
cells will spontaneously transform upon passages above 10-15.  
 
Characterization of CXCR2 CAMs in mammalian cells 
  To characterize the constitutive activity of the different CXCR2 CAMs, 
NIH3T3 stable cell lines were assessed for anchorage independent growth and 
the loss of contact inhibition [192]. Additionally, impedance measurements 
allowed quantitative measurements of cellular proliferation and morphological 
changes associated with cellular transformation. This electrochemical technique 
has been applied to biological studies that include cellular barrier function, 
attachment, spreading, and adhesion [193] [194] [195] [196]. To characterize the 
specific genes that may be involved these morphological changes, luciferase 
reporter assay were utilized. For example, Cannon and Cesarman [197] 
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demonstrated that KSHV ORF74 constitutively activates transcription of AP-1, 
NF-kB, CREB, and NFAT-responsive promoters using luciferase assays. The 
ultimate test of whether these CXCR2 CAMs lead to tumorgenicity, was the 
implantation of cells into the hind flank of nude mice and measuring tumor 
formation in vivo. 
 
Foci formation assay 
 Seed 100 stably transfected NIH3T3 cells on top of 2×105 untransfected 
NIH3T3 cells in normal growth medium with a CXCR2 antagonist, SB225002 
(Calbiochem) added to a final concentration of 1µM. This is added in order to 
prevent growth of the WT CXCR2 transfectants, which may respond to CXC 
chemokines present in the serum.  Change the growth media every 2 or 3 days. 
After 5-7 days the cells should start to form colonies.  10-14 days after initial the 
seeding, fix the cells in 70% ethanol and stain with crystal violet solution. If the 
cells grow too fast and begin to detach from the plate, stop the culture earlier and 
fix and stain. To enumerate the number of colonies, photograph the well and 
analyze the images using ImageJ version 1.43 (Rasband, W.S., ImageJ, U. S. 
National Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 
1997-2009). 
 
Soft-agar growth assay 
 Blend a total of 1×103 stably transfected NIH3T3 cells in pre-warmed 
(37°C) 0.4 % soft-agar containing regular medium, and then pour the mixture on 
	   57	  
top of 0.8 % agar in a 6-well plate. Feed cells every 3 days with 5 drops of media 
per well. After incubation for 3 weeks, add 500 µl of 0.5 mg/ml p-
iodonitrotetrazolium violet and incubate for overnight at 37°C.  Photograph wells 
and visualize colonies under an image analyzer (LAS 4000, Fujifilm Co.). Count 
and measure the number and size of colonies using ImageJ. 
 
Electrical impedance measurements for cellular proliferation  
 Figure 5 shows schematic diagrams, three key factors, and exemplified 
images in regard to cellular micro-impedance measurement. Impedance is the 
frequency-dependent opposition of a conductor to the flow of an alternating 
electrical current. An alternating current is used for bioelectrical impedance 
measurement because it penetrates the cells at low levels of voltage and 
amperage. The corresponding experimental setup consists of lock-in amplifier, 
data acquisition board, computer, and electrodes. Dynamic biophysical analysis 
is followed by cellular micro-impedance data obtained by using LabVIEW 
(National Instruments Corp.). An ac 1 Vrms reference signal via a series 1 MΩ 
resistor is provided as a reference voltage. A National Instruments SCXI-1127 
switch is successfully employed to connect the various working electrodes with 
the counter electrode of each array.  The source voltage generator resistance 
(Rs) was 50 and the input impedance equivalent to a parallel resistor (Rv) and 
capacitor (Cv) combination of 10 MΩ and 10pF, respectively.  
         During the cellular micro-impedance scans, data is acquired at a rate of 32 
Hz for 2 seconds using a 30 ms filter time constant and 12 dB/decade roll off.  
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Averages and standard deviation estimates are obtained from the 64 sampled 
data points over the 2 second time intervals. During the experiments, cultures are 
maintained at 37 °C and 5% CO2. Naked scans are always preceded to optimize 
the sensitivity, to check for any electrodes debris or defects and, most 
importantly to be used as reference levels for normalization. After repeated 
careful examination to select pertinent a cell density, a total of 3×104 
transfectants and untransfected NIH3T3 cells are inoculated in 400 µl normal 
growth medium onto the electrode. One well remained untreated to provide a 
control.  
 
Electrical impedance measurements for the foci formation 
assay 
        The impedance apparatus, as described above, is also employed to 
dynamically examine colony-like foci formation of mutated cell lines. 400 µl of 
normal growth medium containing 6×104 untransfected NIH3T3 cells is filled in 
each well to produce a cellular base layer providing growth factors. A total of 
3×104 transfectants, or untransfectant controls, are seeded on top of the 
untransfected NIH3T3 layer.  Seeding is performed at the saturated growth time 
point (approximately 27 hours) with another 100 µl normal growth medium. 
Impedance measurements continue without any interruption during the seeding 
process for another 61 hours to produce a second set of scans. Time-dependent 
changes in the normalized resistance and reactacne can be obtained in real time.  
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Figure 5. Overview of cellular micro-impedance measurement.  
Impedance measurements reflect the electrical resistance and reactance across 
a cellular membrane and through a cell monolayer. (A) Schematic drawings show 
current flows before and after cell inoculation.   Each chamber contains a 
substrate with an electrode, a layer of conductive material, an insulation layer 
and a small chamber containing the cellular growth medium. As cells attach, 
there is a modification of the current flow.  (B) This drawing shows the three 
important parameters in impedance measurements, which characterize the 
cellular barrier (1) the current flow under the cells (2) the current flow between 
the cells and (3) the capacitively coupled current through the cellular 
membranes. (c) Cellular growth images on 250-micron diameter electrodes. 
These photomicrographs show cellular changes in their morphology, their 
adherence to each other, and to the substrate over time. 
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The bioelectrical impedance measurement can provide an invasive, sensitive, 
and quick ways of dynamically examine cellular physiological changes. 
 
Luciferase reporter assays 
 To measure the basal level of NF-κB, transiently co-transfect HEK293 
cells (4.0×105), in a 6-well plate, with 2.0 µg of 3X MHC-Luc [198], 0.5 µg of pRL-
CMV as an internal control, and 0.5 µg of CXCR2 constructs with 
LipofectamineTM 2000 (Invitrogen). At 24 h posttransfection, synchronize 
transfected cells by serum starvation and then harvest.  Assay cells with Dual-
GloTM Luciferase Assay System following manufacturer’s instructions (Promega). 
 
Tumor Formation in vivo 
 Subcutaneously inject stably expressed NIH3T3 (2×105/mice) into the 
flanks of 6 to 8 week old athymic nu/nu mice (Jackson Laboratory). The protocol 
for this animal experiment was reviewed and approved by the Institutional Animal 
Care and Concerns Committee of the University of Tennessee.  Once tumors are 
beginning to appear to be seen (from 3-4 wks), measure daily. If one member in 
the group achieved a tumor size of 1.5 cm, all members of the group were 
euthanized.  Resect, measure and place tumors into 10% buffered formalin.  Cut 
thin sections and stain with hematoxilin and eosin to characterize the types of 
cells that have infiltrated and the morphology of the tumors themselves. 
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CHAPTER 4. RESULTS 
 
Receptor expression in the S. cerevisiae strains CY1141 and 
CY12946   
 To identify the expression of CXCR2 CAMs in the yeast, 
Immunofluorescence and subcellular fractionation were used to demonstrate 
proper expression and cellular localization before beginning CXCR2 CAM 
selection. Yeast strains, CY12946, expressing CXCR2 stained with an anti-
CXCR2 antibody (E-2, SantaCruz Biotechnology), and a nuclear was stained 
with Hoechst  (Molecular Probe) (Figure 6). Since the localization of the CXCR2 
is not precisely distinguishable, subcellular fractionation was accomplished 
(Figure 7). Yeast strain, BJS21, is known to express yeast pheromone (α-factor) 
receptor, Ste2p, on the plasma membrane, which is a positive control (Figure 
7A). CXCR2 stained with antibody specific CXCR2 show a same fraction with 
Ste2p in BJS2i, which indicate CXCR2 localized to the plasma membrane like as 
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Figure 6. Human CXCR2 expression in transformed yeast strains.  
Spheroplasts were generated from CXCR2 untransformed (-) and transformed 
(+) yeast strain, CY12946. Cells were fixed and stained with an anti-CXCR2 
antibody (E-2, SantaCruz Biotechnology) and a nuclear stain (Hoechst, 
Molecular Probe). Cells were observed and photographed using an Olympus 
BX50 fluorescence microscope (100x magnification) equipped with a CCD 
camera and analyzed using pictureframe version 2.3 (Olympus). 





Figure 7. CXCR2 is expressed in the CY12946 strain and localizes to the 
plasma membrane.  
Total membrane preparations from control strain, BJS21 that expresses Ste2p 
[199], and CXCR2 transformed strain CY12946 (+) were run over a 4 ml sucrose 
gradient (30-60%) and 250 ul fractions were collected from the bottom to the top 
of the tube. 10 ul of each fraction was run on the SDS PAGE gel and 
immunoblotted with either (A) anti-FLAG antibody or (B) CXCR2 (E-2, Santa 
Cruz Biotechnology) followed by anti-mouse HRP antibody. Blots were 
developed with ECL (Amersham). 





PART III. Electrical impedance measurements predict 
cellular transformation 
Published as “Electrical impedance measurements predict cellular 
transformation” Giljun Park, Chang K. Choi, Anthony E. English, Tim E. 
Sparer in Cell Biol. Int. 2009 Mar;33(3):429-33. Epub 2009 Jan 27. 
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CHAPTER 1. ABSTRACT 
 
 Cellular transformation is the first step in cancer development. Two 
features of cellular transformation are proliferation in reduced serum and 
anchorage independent growth. Impedance measurements have been used to 
measure proliferation and attachment in normal cells. This study describes the 
use of impedance measurements to distinguish normal cells from transformed 
cells. NIH3T3 cells were transformed with a constitutively active chemokine 
receptor (D143V_CXCR2) and growth in reduced serum and anchorage 
independent growth were measured using established biological assays and 
compared to impedance measurements. The results of this study show that 
impedance measurements provide a quick and reliable way of measuring cellular 
transformation.  
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CHAPTER 2. INTRODUCTION 
 
 In Europe, there were approximately 1.7 million deaths due to cancer in 
2006 [200]. Understanding the cellular processes involved in the transformation 
of a normal cell into a cancerous cell will lead to more effective cancer 
treatments. There are five characteristics of transformed cells: immortalization, 
growth in reduced serum, anchorage independent growth, loss of contact 
inhibition, and tumor formation in nude mice. Mutations in cell cycle control genes 
[201], growth factors [202], transcription factors [203] and degradation pathways 
[204] can lead to cellular transformation. One of these triggers is the over 
expression of a constitutively active chemokine receptor, CXCR2 [93]. The 
receptor normally functions to induce cellular activation, but when it is 
constitutively active, it induces cellular transformation. A single point mutation, 
Aspartic acid (D)  Valine (V) at position 143, on this receptor causes the 
continuous activation of signaling pathways leading to transformation [114]. 
Using this receptor for the transfection of mouse fibroblasts as model for cellular 
transformation, the ability of impedance measurements to discern transformed 
cells from normal cells was assessed. 
 Giaever and Keese [205, 206] pioneered the use of small micro-electrodes 
with a large counter electrode to measure cellular impedances. Impedance 
measurements are based on the electrical resistance and reactance across a 
cellular membrane and through a cell layer. This electrochemical technique has 
been applied to biological studies that include cellular barrier function, 
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attachment, spreading, and adhesion [193, 195, 196, 207]. In addition, frequency 
dependent electrical impedance measurements have been used to evaluate the 
model parameters associated with cell-cell and cell-matrix junction formation 
[208-210]. In this study, micro-impedance measurements are used to 
quantitatively examine the proliferation and the morphological changes 
associated with cellular transformation. 
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CHAPTER 3. MATERIALS AND METHODS 
 
Cell lines and expression vector 
NIH3T3 mouse fibroblasts (ATCC, Manassas, VA), cultured in DMEM 
(Dulbecco’s modified Eagle’s medium) containing 10% Fetal Calf Serum (FCS) 
(Hyclone, Logan, UT), were transfected with pRc/CMV (Invitrogen) expressing 
either WT_CXCR2 or D143V_CXCR2 with the Lipofectamin TM 2000 (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions. Stable transfectants 
were selected with 800 µg/ml of G418. 
 
Mutagenesis 
To generate D143V_CXCR2, the WT_CXCR2 pRc/CMV expression 
plasmid was mutagenized using the complementary primers (D143V_Forward: 
5’-GCA TCA GTG TGG TTC GTT ACC TGG CCA TTG TCC ATG C-3’; D143V_ 
Reverse: 5’-GCC AGG TAA CGA ACC ACA CTG ATG CAG GCC AGT AGC -3’) 
and a modified QuickChange® method (Stratagene).  Briefly, Takara LA taqTM 
polymerase (Takara Bio, Madison, WI) was used for the mutagenesis. Dpn І 
treatment was followed by PCR amplification (98 °C for 3 min, 35 cycles of 98 °C 
for 30 sec, 55 °C for 30 sec, and 1 cycle of 72 °C for 10 min and 72 °C for 20 
min). The PCR reaction, initially cleaned with a QIAquick PCR purification kit 
(QIAGEN, Valencia, CA), transformed the plasmid DNA into MAX Efficiency® 
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DH5α™ Competent Cells (Invitrogen, Carlsbad, CA). Mutants, set up without 
polymerase and/or without a primer, provided negative controls. 
 
Focus formation assay 
 The focus formation assay was performed based on Burger et al. [93]. 
One hundred stably transfected NIH3T3 cells were seeded on top of 2x105 
untransfected NIH3T3 cells in normal growth medium with 1 µM of CXCR2 
inhibitor (SB 225002, Calbiochem, San Diego, CA). Foci were photographed and 
counted after 2 weeks incubation at 37 °C and 5% CO2. 
 
Cellular Proliferation Assay  
 Stable transfectants expressing either WT_CXCR2, D143V_CXCR2, or 
untransfected NIH3T3 cells were plated at 1×105 cells and grown in reduced (2%) 
serum at 37 °C and 5% CO2.  At the time points indicated, cells were trypsinized, 
stained with trypan blue (Freshney, 1987), and counted using a hemocytometer 
(Bonifacino, 2001).   Each time point was measured in triplicate. 
 
Electrical impedance measurements for the cellular 
proliferation assay 
 Figure 8 shows a schematic diagram of the micro-impedance 
measurement apparatus. A data acquisition and analysis system was  
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Figure 8. Electrical impedance measurement system schematics.  
(a) A 1Vrms signal is applied to an electrode via a 1MΩ resistor, Rcc. The source 
resistance, Rs, is 50Ω and the input impedance to the lock-in amplifier is 
equivalent to a parallel combination of a 10MΩ resistor and 25pF capacitor, Rv 
and Cv, respectively. The reference cable coaxial leads and lock-in amplifier 
coaxial leads introduce parallel capacitances Cps and Cpv, into the circuit. The 
electrode impedance, Zc, is estimated by voltage measurements and a voltage-
to-impedance conversion based on this circuit. (b) An environmental chamber 
maintains a humidified, 37°C and 5% CO2 atmosphere for dynamic long time-
lapse measurements. The measured impedance is a function of the current flow 
under the cells, between the cells, and the capacitively coupled current through 
the cell membranes. 
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implemented using LabVIEW (National Instruments Corp.). A reference voltage 
source provided an ac 1 Vrms reference signal via a series 1 MW resistor, Rcc, 
to a gold electrode array (Applied Biophysics).  A National Instruments SCXI-
1127 switch made successive connections between the various working 
electrodes and the counter electrode of each array.  The source voltage 
generator resistance, Rs, was 50W.  An SR830 lock-in amplifier (Stanford 
Research Instruments) with an input impedance equivalent to a parallel resistor, 
Rv, and capacitor, Cv, combination of 10 MW and 10 pF, respectively, measured 
the electrode voltage.  Direct measurements of the cable parasitic capacitances 
were made using an LCR meter and incorporated into a circuit model to estimate 
the impedance based on the lock-in amplifier voltage measurements.  
 Preliminary naked scans were performed to optimize the sensitivity and to 
check for any electrodes debris or defects. A total of 3x104 transfectants and 
untransfected NIH3T3 cells were inoculated in 400 µl normal growth medium with 
1 µM of CXCR2 inhibitor, SB225002, onto the electrode. One well remained 
untreated to provide a control. 
 
Electrical impedance measurements for foci formation  
Using the impedance apparatus, as described above, electrodes were 
inoculated with 400 µl of normal growth medium containing 6x104 untransfected 
NIH3T3 cells to produce a cellular base layer providing growth factors. A total of 
3x104 transfectants, or untransfectant controls, were seeded on top of the 
NIH3T3 layer.  Seeding was performed at the saturated growth time point 
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(approximately 26 hours) using 100 µl of normal growth medium in the presences 
of a CXCR2 inhibitor to give a 1 µM final concentration.   Impedance 
measurements were acquired for another 61 hours to produce a second set of 
scans. During the cellular micro-impedance scans, data was acquired at a rate of 
32 Hz for 2 seconds using a 30 ms filter time constant and 12 dB/decade roll off.  
Averages and standard deviation estimates were obtained from the 64 sampled 
data points over the 2 second time intervals. During the experiments, cultures 
were maintained at 37 °C and 5% CO2.  
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CHAPTER 4. RESULTS 
 
Impedance measurement for measuring cellular proliferation 
 One of the hallmarks of cellular transformation is growth in reduced 
serum.  In order compare micro-impedance measurements with traditional 
measurements of cellular growth, the growth of stable transfectants were 
measured in reduced serum media.  Figure 9A shows the results of harvesting 
and counting the cells at different time points.  The D143V transfectant 
proliferation rate is significantly greater (p<0.00001) than the WT_CXCR2 or 
untransfected controls.  Figures 9B and 9C summarize the resistance and 
reactance micro-impedance measurements that were carried out in parallel with 
the growth measurements shown in Fig. 9A.  Although resistance measurements 
initially did not show a marked difference between WT_CXCR2 and 
D143V_CXCR2, at 58hrs (35000 min.) the WT_CXCR2 growth plateaued while 
D143V_CXCR2 continued growing for the remainder of the experiment (Figure 
9B). Micro-impedance fluctuations, a measurement of cellular 
motility/attachment, were also consistently higher in transformed cells. The 
reactance measurements, however, more closely mimicked the growth curves 
generated with more traditional hemacytometer measurements.  These data 
show that impedance measurements can be used to distinguish growth patterns 
of transformed cells compared to non-transformed cells. 
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Figure 9. Impedance measurements distinguish the growth rates of 
transformed verses untransformed cells.   
Stable transfectants expressing either WT_CXCR2, D143V_CXCR2, or 
untransfected NIH3T3 cells were grown in reduced (2%) serum and counted at 
different time points (A). Each data point represents the mean (± s.e.m.) of three 
independent experiments; (B) Normalized resistance (Rc-Rn)/Rn, recorded at 5.62 
kHz, and (C) normalized reactance (Xc-Xn)/Xn, recorded at 56.2 kHz, for the 
direct inoculation of untransfected and transfected NIH3T3 cells.  The terms R 
and X represent the resistance and reactance, respectively and the subscripts c 
and n indicate cell covered and naked scans, respectively. 
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Foci formation can be detected with impedance measurements 
 The loss of contact inhibition during cellular transformation allows these 
cells to grow on top of one another forming foci.  Historically, foci were counted 
visually after staining with a dye such as crystal violet.  Using this technique, the 
number of foci formed with either WT_CXCR2 or D143V_CXCR2 transfectants 
(Figure 10A, 10B) was quantified.  These data show that the transformed cells 
(D143V_CXCR2) form significantly more foci than WT_CXCR2 (p<0.00001).   
 To compare these findings with the micro-impedance measurements, 
impedance measurements using an experimental set up similar to the one 
described above.  The main difference is that a monolayer of untransfected 
NIH3T3 cells is attached to the electrode to provide growth factors for foci 
development.  In spite of this more complex set up, both resistance (Figure 10C) 
and reactance measurements (Figure 10D) show that D143V_CXCR2 attaches 
and proliferates much more rapidly than either WT_CXCR2 or untransfected 
cells. This illustrates that impedance measurements can accurately measure foci 
formation as an indicator of cellular transformation.  
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Figure 10. Impedance measurements assess increased attachment and foci 
formation in transformed cells.   
In parallel with impedance measurements, foci were measured after 2 weeks. 
Stable transfectants expressing either WT_CXCR2, D143V_CXCR2, or 
untransfected NIH3T3 cells were seeded on top of the untransfected NIH 3T3 
cells, and cultured in the presence of CXCR2 inhibitor (SB 225002, Calbiochem). 
(A) An example of the foci that were counted is representative of three 
independent experiments.  (B) No foci were detected on the untransfected 
contols.   Bars represent the mean ( ± s.e.m.) of three independent experiments 
each carried out in triplicate.   Impedance measurements were carried out under 
a similar experimental setup.  (C) Normalized resistance (Rc-Rn)/Rn, recorded at 
5.62 kHz, and (D) normalized reactance (Xc-Xn)/Xn, recorded at 56.2 kHz, for 
untransfected and transfected NIH3T3 cells.  The terms R and X represent the 
resistance and reactance, respectively, and the subscripts c and n indicate cell 
covered and naked scans, respectively. For the sake of clarity, symbols 
represent 30 data intervals. The arrows indicate the point of addition of either the 
transfectants or untransfected controls. The increases in resistance and 
reactance are consistent with increased cellular proliferation and multi-layer 
focus formation. 
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CHAPTER 5. DISCUSSION 
 
 Several well-known methods to examine cell proliferation include 
fluorescence microscopy, flowcytometry, and biochemical assays [211]. While 
these methods are stationary and need fluorescent or radioactive probes, micro-
impedance measurements are a bio-analytical technique capable of non-
invasively and dynamically monitoring proliferation in real time without the use of 
chemical probes. Another benefit is its high sensitivity to distinguish between 
transformed and untransformed cells. Both the resistance and reactance of 
transformed cells increased faster and to larger values than WT_CXCR2 or 
untransfected NIH3T3. 
 The measured impedance is a sensitive and complicated function of the 
degree of cellular proliferation, cell-matrix attachment, and cell-cell attachment. 
As the cells proliferate and attach to the surface and each other, a systematic 
increase in the measured impedance occurs.  Uncontrolled proliferation 
characteristic of transformed cells is, therefore, consistent with the systematic 
impedance increase observed in this study. Although, the actual impedance 
values vary between different experiment runs, this pattern was consistently 
observed with transformed cells compared to untransformed cells. The increase 
in the microimpedance fluctuations is also consistent with increased micromotility 
associated with transformed cells. 







PART IV. Novel constitutively active point mutations in 
the NH2 domain of CXCR2 capture the receptor in 
different activation states 
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CHAPTER 1. ABSTRACT 
 
 The chemokine receptor, CXCR2, is a member of the rhodopsin family of 
GPCRs. Normal CXCR2 activation leads to cellular migration, wound healing, 
and angiogenesis. Using a high throughput yeast screen we identified a novel 
point mutation, D9H, which leads to constitutive activation (CA). Generation of 
stable transfectants expressing mutant CXCR2s (either D9H or positively 
charged substitutions, D9K and D9R, or D143V as a positive control) showed 
that all lead to CA but differential levels of cellular transformation (i.e. foci 
formation and soft agar growth). To further investigate how D9 mutations lead to 
differential CA, we used pertusiss toxin (PTX) sensitivity in foci formation assays 
to show that D9R uses the Gαi like WTCXCR2 and D143V, while D9H and D9K 
do not. All CA receptors use the JAK pathway based on sensitivity to the 
inhibitor, AG490. Phosphorylation of PLC β3 and the sensitivity of foci formation 
to the inhibitor of PLC β3, U73122, demonstrates that all utilize the Gαq subunit. 
Interestingly, D9R receptors use both Gαi and Gαq. The CA receptors induce 
phosphorylation of the epidermal growth factor receptor (EGFR), which suggests 
transactivation between CXCR2 and EGFR. These data illustrate two novel and 
important findings. First, the amino terminus of CXCR2 controls activation and 
signaling via multiple G protein subunits to elicit downstream signaling. Second, 
our work supports the “functional selectivity” model for GPCR activation., The 
different CA CXCR2s, mimicking agonist activation, have multiple conformations 
that lead to differential activation. 
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CHAPTER 2. INTRODUCTION 
 
 Although there are many contributing factors in tumorigenesis, 
chemokines and their receptors play a role in tumorigenesis and metastasis 
[134]. Chemokines function normally as small chemoattractant cytokines that are 
involved in inflammatory, developmental, and homeostatic processes [174]. 
Deregulation of this system is associated with the development of cancers and 
metastasis. One possible deregulation of chemokine activity is the constitutively 
active mutant (CAM) receptor [134, 175]. CAM receptors cause the alteration of 
structural constraints leading to an active conformation.  This change induces 
ligand independent activity called constitutive activity [176]. The CAM GPCR is a 
valuable model for explaining the basic molecular events involved in the 
development of a variety of human diseases [177]. The best example of 
chemokine receptor constitutive activity and cancers is the Kaposi sarcoma 
herpesvirus chemokine receptor, ORF74, which has a ‘VRY’ motif instead of 
‘DRY’ motif between third transmembrane domain and second intracellular loop 
and has been shown to be constitutively active [93, 106, 178].  
 CXC chemokine receptor 2 (CXCR2) is a G-protein-coupled receptor 
(GPCR) [179] expressed on neutrophils, some monocytes, endothelial cells, and 
some epithelial cells [152] (Figure 11). Activation of CXCR2 with ELR+ CXC 
chemokines is responsible for the leukocyte migration, degranulation, cellular 
differentiation, and ELR+ CXC chemokine mediated  




Figure 11. Schematic diagram of the human CXCR2 receptor.  
CXCR2 consists of seven transmembrane domains (TM I – TM VII) connected by 
three extracellular (EC I - EC III) and three intracellular (IC I- IC III) loops. The 
conserved DRY box is shaded and the D9 residue is indicated with an arrow.  
The transmembrane domains were predicted using HMMTOP, TMPred, and 
PHD.  
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angiogenesis [123]. Binding and activation of CXCR2 with CXCL1 (Groα) was 
shown to increase melanoma growth [212]. The degree of CXCR2 expression 
was shown to correlate with metastasis in a nude mouse [213]. Moreover, 
CXCR2 expression is related to of the metastatic potential in renal carcinomas 
[165], adult myeloblastic leukemias [214], liver [215] and lung cancers [159]. The 
most extensive evidence for CXCR2 expression/transformation/metastasis 
comes from melanomas. CXCR2 is found on highly malignant melanoma cell 
lines as well as from isolates of human melanomas [161, 216-218]. 
 In GPCRs that have been mutagenized in vitro to generate CAMs, most 
mutations mapped to the transmembrane regions, C-terminal region, and second 
and third intracellular loops [81, 219]. However, no mutations or deletions in the 
N-terminal domain have been identified that result in a constitutively active 
chemokine receptor. 
 In this study, human CXCR2 is expressed a genetically engineered yeast 
strain of Saccharomyces cerevisiae to screen for potential CXCR2 CAMs. 
Randomly mutagenized copies of the CXCR2 ORF cloned into a yeast 
expression plasmid allows for an unbiased selection of CAM receptors. From this 
yeast screen we described a single amino acid substitution in the N-terminal 
region of CXCR2 leads to a constitutively active CXCR2. Substitution of the 
aspartic acid residue (D9) to amino acids with different properties results in 
constitutive activity in yeast. These CAM receptors expressed in NIH3T3 cells 
induce cellular transformation as evaluated by foci formation, anchorage-
independent growth in soft agar and tumorigenesis in nude mice. In addition, 
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these constitutively active receptors lead to a PLC β3 mediated signal 
transduction cascade potentially induced by Gαq/11 as well as NF-κB activation, 
which plays an important role in transactivation of angiogenic CXC chemokines 
[220]. 
 Our results suggest that the N-terminal domain of the CXCR2 plays an 
important role in the regulation of structural constraints that serve as regulators of 
receptor activation. In addition, differential usage of Gα proteins, such as Gαi 
and/or Gαq/11, induced with the different CAM CXCR2 addresses important 
aspects of functional selectivity. 
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CHAPTER 3. MATERIALS AND METHODS 
 
Yeast strains and expression vector 
 Genetically modified Saccharomyces cerevisiae strains, CY1141 (MATα 
far1Δ1442 FUS1p-HIS3 ste14::trp1::LYS ste3Δ1156 gpa1(41)-Gαi2 lys2 ura3 
leu2 trp1 his3) [185] and CY12946 (MATα FUS1p-HIS3 GPA1Gαi2(5) can1 
far1Δ1442 his3 leu2 sst2Δ2 ste14::trp1::LYS ste3Δ1156 tbt1-trp1 ura3) [186], 
were a generous gifts from Dr. J. Broach (Princeton University). The plasmid 
p426 (ATCC #87361) contains the wild type or mutated CXCR2 gene under the 
control of a constitutively active promoter (GPD) and URA3 auxotrophic marker. 
Yeast cells were transformed each plasmid construct by the lithium acetate 
transformation method [221].  
 
β-galactosidase assay 
 Plasmid pMD1325 (a gift from Dr. Dumont M.E., University of Rochester, 
School of Medicine and Dentistry) contains a FUS1-lacZ gene that is induced by 
receptor activation [188]. β-galactosidase assays was performed as previously 
described [191]. Briefly, yeast transformed with either wild type CXCR2 or 
mutants and pMD1325 were grown overnight in selective growth medium at 30°C 
to 5×106 cells/ml, washed by centrifugation, and grown for one doubling based 
on hemocytometer count at 30°C. Basal activity of β-galactosidase was 
measured by using a yeast β-galactosidase assay kit (Pierce) according to the 
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manufacturer's protocols, activation is measured in Miller units. Comparing β-




 Random mutagenesis was performed by error-prone PCR [189]. Primers 
upstream and downstream of the CXCR2 ORF were synthesized to include 
unique restriction sites (HindIII and XbaI).  These were used in a mutagenic PCR 
reaction that had three modifications in order to increase the mutagenic potential 
of the reaction.  First, low fidelity Taq polymerase was used (Takara Biosystems).  
Secondly, the ratio of nucleotides used was altered to increase mistakes in the 
polymerase. dTTP/dCTP was adjusted to 0.8 mM (final conc.) while the other 
nucleotides remained at 0.25 mM [190]. Finally, manganese chloride was added 
to final concentration of 500nM. 
 
Immunofluorescence Microscopy 
 2.0×105 NIH3T3 and stable transfectant cells grown on Lab-Tek II 
Chamber Slide (Nalge Nunc) were fixed with 4% paraformaldehyde for 10 min at 
room temperature, permeabilized with Triton X-100 (0.01% in PBS) for 5 min, 
and blocked with goat serum (1% BSA and 10% goat serum in PBS). Cells were 
washed three times with 1ml of PBS. After incubated with mouse monoclonal 
Na+/K+-ATPase (1:100, Santa Cruz Biotech) as a marker for plasma membrane 
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localization for 2 h, cells were washed three times and incubated with rabbit 
polyclonal anti-CXCR2 antibody (1:500, Abcam) at 4°C overnight. After washing 
three times, cells were stained with Alexa Flour 488-conjugated goat anti-rabbit 
IgG (1:500, Molecular Probes) and Alexa Flour 633-conjugated goat anti-mouse 
IgG (1:200, Molecular Probes) for 30 min. After washing three times, cells were 
mounted by SuperMount medium (BioGenex) and sealed with cover slip. The cell 
was photographed with confocal laser scanning microscope (SP2 LSCM, Leica 
Microincorporation Inc.) and analyze with ImageJ version 1.43 (Rasband, W.S., 




 Selective CXCR2 inhibitor (SB225002, Cat.No. 559405), JAK inhibitor 
(AG490, Cat.No. 658411), and Gαi inhibitor (Pertussis Toxin, Cat.No. 516562) 
were purchased from Calbiochem. Phospholipase C inhibitor (U73122, Cat.No. 
U6756) was purchased from Sigma-Aldrich. 
 
Plasmids, Cell lines and Transfection 
 cDNA encoding human CXCR2 was provided by Dr. Philip M. Murphy 
(National Institutes of Health). The luciferase reporter plasmid 3X MHC-Luc was 
provided by Dr. Albert S Baldwin, Jr. (University of North Carolina School of 
Medicine, Chapel Hill), and pRL-CMV (promega) was a gift from Dr. William E. 
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Miller (University of Cincinnati College of Medicine, Cincinnati). Mouse fibroblasts 
(NIH3T3) and human embryonic kidney cells (HEK293) were cultured in DMEM 
(Dulbecco’s modified Eagle’s medium) containing 10% Fetal Clone (FC) 3. 
Immortalized mouse melanocyte cell line, parental melan-a (a gift from Dr. Ann 
W. Richmond, Vanderbilt University School of Medicine) was cultured as 
previously described [222]. LipofectaminTM 2000 (Invitrogen) was used for both 
transient and stable transfections.  Stable cell lines (NIH3T3 or parental melan-a) 
were selected with 800 µg/ml of G418 (Mediatech Inc.). 
 
Site-Directed Mutagenesis 
 Single point mutations of CXCR2 in pcDNA3 were induced using the 
QuikChange site-directed mutagenesis kit (Stratagene) according to the 
manufacturer’s protocols. Mutations were confirmed by sequencing. 
 
Single Nucleotide Polymorphism Genotyping 
 PCR for genotyping was done as followed by Masi et al [223]. The CXCR2 
coding region from either genomic DNA of lung cancer cell lines were amplified 
with the following primers: CXCR2 Forward with HindIII: 5’- 
CCCAAGCTTATGGAAGATTTTAACATGGAGAGTG-3’ and CXCR2 Reverse 
with XbaI: 5’-GCTCTAGATTAGAGAGTAGTGGAAGTGTGC-3’. 
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Cellular transformation assays 
 The cellular transformation assay was performed as previously described 
[93]. For foci formation assay, 100 stably transfected NIH3T3 cells were seeded 
on top of 2.0×105 untransfected NIH3T3 cells in normal growth medium with 1 µM 
of CXCR2 inhibitor (SB 225002, Calbiochem). Foci were photographed and 
counted after 2 weeks. For the anchorage-independent growth assay, a total of 
1.0×104 stably transfected NIH3T3 cells were cultured in 0.3 % agar containing 
regular medium with SB 225002, on top of 0.6 % agar. Cells were fed every 3 
days with 5 drops of growth media, and photographed after 3 wk. Photographed 
images were analyzed using ImageJ version 1.43 (Rasband, W.S., ImageJ, U. S. 




 NF-κB reporter assay was performed based on Sherril et al. [198]. To 
measure basal level of NF-κB, HEK293 cells (4.0×105) were transiently co-
transfected in a 6-well plate with 2.0 µg of 3X MHC-Luc, 0.5 µg of pRL-CMV as 
an internal control, and 0.5 µg of CXCR2 constructs with LipofectamineTM 2000 
(Invitrogen). At 24 hours post-transfection, transfected cells were synchronized 
during 24 hours, and then assayed with Dual-GloTM Luciferase Assay System 
following manufacturer’s protocol (Promega). 
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Immunostaining for CXCR2 and phosphorylated signaling 
molecules 
 For the staining of stable CXCR2 transfectants, PE-conjugated CXCR2 
specific antibody (R&D Systems, Cat.No. FAB331P) was utilized. Analysis of 
phosphorylated signaling molecules was performed as previously described 
[224]. Briefly, stably transfected NIH3T3 cells were serum starved during 24 hrs 
and fixed with 70% ethanol at -20°C for at least 1 hr, and then permeablized with 
0.25% Triton X-100 in PBS on ice for 15 min. Permeablized cells were blocked 
with 1% goat serum at room temperature for 30 min, and then cells were stained 
with antibody specific phosphorylated PLC β3 (Santacruz Biotech. Cat.No. sc-
34392) and PKC α/β2 (Cell Signaling, Cat.No. 9375). Alexa Fluor® 488 
(Invitrogen) was used as a secondary antibody. 
 
Tumor Formation in vivo 
 Stably expressed NIH3T3 (2×105/mice) were injected subcutaneously into 
the flanks of 6 to 8 wk old athymic nu/nu mice (Jackson Laboratory). The protocol 
for animal experiment was reviewed and approved by the Institutional Animal 
Care and Concerns Committee of the University of Tennessee. 
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CHAPTER 4. RESULTS 
 
Screening for CXCR2 CAMs using a genetically modified 
Saccharomyces cerevisiae high-throughput system 
 Genetically modified yeast strains, CY1141 and CY12946, were used to 
identify CXCR2 CAMs. CY1141 expresses a hybrid G alpha subunit, which 
encodes the first 33 N-terminal residues of human Gαi2 replaced with the first 41 
N-terminal residues of the endogenous yeast GPA1 protein. CY12946 contains a 
modified Gα subunit with the last 5 C-terminal residues of yeast GPA1 replaced 
with human Gαi2. These genetically modified G proteins allow coupling to the 
mammalian receptor, which induces the yeast pheromone responsive signaling 
pathway (Figure 12). To identify CXCR2 CAMs, wild type CXCR2 (WT_CXCR2) 
was randomly mutated using error prone PCR and cloned into the yeast 
expression vector, p426GPD. This plasmid contains an origin of replication, a 
glyceraldehyde-3-phosphate dehydrogenase (GPD) promoter driving expression 
of the inserted open reading frame, and a uracil (URA) auxotrophic marker. 
Transformation into the above mentioned yeast strains allowed for the selection 
of CXCR2 CAMs that activated the signaling pathway, which leads to activation 
of the pheromone responsive element and the gene for histidine auxotrophy. in 
the presence of 3-AT.  
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Figure 12. Schematic of yeast signaling used to identify CXCR2 CAMs.   
 Knock-out genes are showed in grey and an “X”. Expression of HIS3 is 
under the control of the Fus1 promoter with a pheromone-response element 
(PRE). The plasmid p426 contains the human CXCR2 gene under the control of 
a constitutively active promoter (GPD) and URA3 auxotrophic marker. CXCR2 
CAMs are selected on media lacking histidine and uracil in the presence of 3-
amino-1,2,4-triazole (3-AT) to suppress endogenous levels of histidine 
biosynthesis. 
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 Approximately 300 yeast colonies grew on the His minus plates and 30 
clones (approx. 30) were sequenced after retransforming the plasmids into 
bacterium. Among them, a single point mutation in the N-terminus of CXCR2 was 
identified as a CAM. The 9th residue (aspartic acid (D)) was mutated to a histidine 
(H). The D9H mutant demonstrated constitutive activity (CA) in a β-galactosidase 
assay in yeast (Figure 13). These factors led us to further investigate the role of 
the 9th residue of CXCR2. To verify the cellular and structural function of the 9th 
residue of CXCR2 in the N-terminus, different single point mutations were 
generated in the 9th residue. Since WT_CXCR2 encodes the negatively charged 
aspartic acid (D) at the 9th residue, we generated mutants encoding positively 
charged amino acids, such as lysine (K), and arginine (R). An asparagine (N) 
substituted CXCR2 was generated because we had identified this mutation from 
a small cell lung cancer (SCLC) line, H69. As mentioned above (Part I in this 
dissertation) mutation of the DRY motif in CXCR2 induces CA. Therefore CXCR2 
DRY mutant, D143V, was also generated and used as a positive control in all 
experiments.  
 After generating the CXCR2 mutants, the constitutive activity of each 
receptor was measured. A β-galactosidase assay was used to measure the 
degree of receptor activation in yeast using FUS1-lacZ reporter construct.  





Figure 13. Constitutive activity of CA CXCR2 measured via β-galactosidase 
activity.  
 Yeast strain, CY1141, contains a plasmid, pMD1325, with the lacZ gene 
under the control of the pheromone responsive element, FUS1. Yeast β-
galactosidase assay kit (Pierce) was used to measure β-galactosidase activity 
and is represented in Miller units. Bars represent the average of three 
independent experiments plus/minus standard deviation. Student’s t-test 
(PRISM(ver. 5.0b)  was used to determine statistical significance versus 
WT_CXCR2 (*; p< 0.05).  
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 CXCR2_D143V shows the highest degree (approx. 20 folds over WT_CXCR2) 
of receptor activation in the yeast. CXCR2_D9H and D9N mutants are also 
higher than background (approx. 12 and 7 fold over WTCXCR2 respectively). 
Also, the activity of CXCR2_D9K and _D9R demonstrate significantly higher 
levels than WT_CXCR2 (p<0.05) albeit less than CXCR2_D9H and _D9N (Figure 
13).  
 
Establishment of NIH3T3 cell lines stably expressing CXCR2 
CAMs  
 NIH3T3 cells, established from NIH Swiss mouse embryo culture, [225], 
have been used historically for identifying transforming events. To identify fully 
transformed cells due to CXCR2 CAMs, we generated clonal, stable NIH3T3 cell 
lines. These lines were then used in various assays for assessing the degree of 
transformation.  
 To verify the expression and localization, confocal microscopy was used 
(Figure 14). As a positive control to verify plasma membrane localization, an 
antibody specific Na+/K+ ATPase (Santa Cruz Biotech) was used. As shown in 
figure 14, WT_CXCR2 and mutants co-localized with Na+/K+ ATPase indicating 
WT_CXCR2 and CXCR2 CAMs are expressed on the plasma membrane. In 
addition to localization, the expression level of each receptor was analyzed using 
flowcytometry (Figure 15). 




Figure 114. Cell surface co-localization of CXCR2 CAMs with Na+/K+ 
ATPase in NIH3T3.  
Stably transfected WT_CXCR2 and CXCR2 CAMs in NIH3T3 were fixed, 
permeablized, and stained with a specific human CXCR2 antibody (Abcam, 
Cat.No. ab14935) and Na+/K+ ATPase (Santa Cruz Biotech. Cat.No. sc-48345). 
Alexa Flour 488 and 633 -conjugated secondary antibodies (Invitrogen) were 
visualized and photographed at a magnification x100 by confocal laser scanning 
microscope. Scale bar indicates 30.0 µm. 
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The surface localization and relative expression level of the receptors for cell line 
were verified with immunostaining followed by flow cytometery analysis (Calibur, 
BD biosciences) (Figure 15). As shown in figure 15, all transfectants had similar 
cell surface expression levels. Therefore, NIH3T3 cell lines stably expressing 
WT_CXCR2 and CXCR2 CAMs had similar expression levels and were then 
used in assays for assessing the degree of transformation. 
 
CXCR2 CAMs induction of cellular transformation  
 Foci formation assays, which indicate the loss of contact inhibition 
between adjacent cells, and growth in soft agar, which mimics anchorage 
independent growth were used as measurements for the degree of cellular 
transformation in our stable cell lines. Foci formation assay was performed by 
seeding 100 stably transfected NIH3T3 cells on top of the untransfected NIH3T3 
cells. NIH3T3 cells expressing CXCR2_D143V, which served as the positive 
control, led to high numbers of foci as was previously report [93] (Figure 16). 
Interestingly, cells expressing the CXCR2 CAMS (D9H, D9K and D9R) also 
induced a high number of foci (average 50 number of foci). However cells 
expressing WT_CXCR2 and CXCR2_D9N induced only a few foci.  These data 
show that CXCR2_D9H, D9K, and D9R  are capable of transforming NIH3T3 
cells while CXCR2_D9N does not. 
 
 




Figure 15. CXCR2 surface expression of stable transfectants.  
Stable NIH3T3 transfectants were stained with PE conjugated CXCR2 specific 
antibody and analyzed with flowcytometry (R&D Systems, Cat.No. FAB331P). 






Figure 16. CXCR2 CAMs differentially induce foci formation.  
As a measure of their transformation ability, foci formation of stably transfected 
WT_CXCR2 and mutants in the presence of CXCR2 antagonist (SB225002, 1 
µM) were measured. Foci were photographed after 2 weeks, except D9K and 
D9R mutants, which were photographed after 10 days. Bars represent the 
average of three independent experiments +/- standard deviation. Student’s t-test 
(PRISM (version 5.0b) was used to determined statistical significance verus 
CXCR2_WT (*; p<0.05).  
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 Since anchorage-independent growth strongly correlates with 
tumorigenicity [226] and tumor metastasis [227], a soft-agar growth assay was 
performed to assess anchorage-independent growth. Compared to WT_CXCR2, 
_D9H,_D9R and_D9K showed significantly a higher number of colonies (Figure 
17). In contrast, CXCR2_D9N was similar to WT_CXCR2. Interestingly, 
CXCR2_D9K and D9R formed a higher number of colonies than CXCR2_D143V 
(approx. 200 and 190 respectively), which is the positive control.  Taken together 
the oncogenic potential of CXCR2 CAMs, such as CXCR2_D143V, D9H, D9K 
and D9R, was verified by their ability to form foci and colonies under soft agar 
under the different conditions. Mutants D9K and D9R demonstrated the most 
oncogenic activity because they had the most colonies and their foci developed 
the fastest. Although CXCR2_D143V and D9H had a lower number of colonies in 
soft-agar, these mutants showed a significant increase (*; p<0.05) compared to 
WT_CXCR2 and D9N.  D9N was similar to background and does not have 
transforming abilities. 
 
CXCR2 CAMs induction of tumor formation in vivo  
 Since CXCR2 mutants induced cellular transformation in vitro, we 
assessed the tumorigenic potential in vivo using hind flank injection of cells in 
nude mice. Stable transfectants were injected subcutaneously into the flanks of 6 
to 8 wk old athymic nu/nu mice (Jackson Laboratory). After inoculation, mice 
were monitored and terminated once tumors reached 1.5 cm in any direction..  
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Figure 17. CXCR2s CAMs lead to differential anchorage independent 
growth.  
Anchorage independent growth (i.e. growth in soft agar) was used as a measure 
of cellular transformation. Each field is representative of the overall colony 
formation in a six well dish (63x). Number of colonies were counted and 
measured using ImageJ. Bars represent the average of three independent 
experiments +/- standard deviation. Student’s t-test (PRISM (version 5.0b) was 
used to determine statistical significance versus WT_CXCR2 (*; p< 0.05). 
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As shown in Table 5, untransfected NIH3T3 cells injected into the flank of nude 
mice did not show any tumor formation, but other mutants, including 
WT_CXCR2, showed tumor formation at the injection site. However 
CXCR2_D9K, D143V and D9H showed aggressive and fast tumor progression 
compared to WT_CXCR2, which required a longer incubation period to form 
tumors. Only 50% of the mice inoculated with cells expressing CXCR2_D9N 
developed tumors and showed slow formation and were terminated at 73 days 
after inoculation. These data indicate that constitutive activity induced by single 
point mutation in the N-terminus of CXCR2 plays an important role in tumor 
formation in vivo. 
 
CXCR2 CAMs Induce differential signal transduction pathways 
during foci formation  
 Based on phenotypic transformation in vitro and vivo, these data strongly 
suggest that CXCR2 CAMs are oncogenic. These CXCR2 CAMs appear to 
induce differential signaling pathways based on the degree of foci formation, soft 
agar growth, and growth in vivo. In order to investigate the signal transduction 
pathways that contribute to cellular transformation, a number of specific signal 
transduction inhibitors were utilized. U73122 specifically inhibits PLC-β, which 
prevents IP3 accumulation [228, 229].  
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Table 5. Differential tumor growth in mice. 
Transfectants Number of mice with 
tumors 
Time until termination 
(Days) 
NIH3T3 0/10 . 
WT_CXCR2 9/10 39 
CXCR2_D143V 10/10 21 
CXCR2_D9H 8/10 21 
CXCR2_D9K 10/10 17 
CXCR2_D9N 5/10 73 
 
 2×105 of NIH3T3 transfectants were injected into the flanks of 6 to 8 wk 
old athymic nu/nu mice. Total mouse inoculated one cell line were termination 
once the tumor develops approx. 1.5 cm from one mouse in each group.  
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The PLC β pathway is downstream of Gαq/11 activation [67, 229]. AG490 was 
used as an inhibitor of Janus Kinases (JAKs) which activate the transcription 
factors (STATs) [230]. As mentioned above PTX prevents Gαi mediated signal 
transduction cascade. Using these inhibits we mapped the downstream signaling 
pathways that are induced in our stable transfectants. 
 As shown in Figure 18, WT_CXCR2 showed transforming potential in the 
presence of IL-8, but in the presence of PTX formation of foci was inhibited 
(Figure 18-A, P<0.05 compared with unstimulated WT_CXCR2). Therefore, 
WT_CXCR2 activation with IL-8 induces Gαi mediated signaling pathways. PTX 
also prevent approximately 50% of foci formation in the case of CXCR2_D143V 
and D9R. However, statistical analysis using student t-test indicated that 
CXCR2_D143V (P<0.05) is different compared with WT_CXCR2. Otherwise 
CXCR2_D9R showed no difference compared with WT_CXCR2 (P>0.05). This 
indicates that G protein usage can be different between WT_CXCR2 and 
CXCR2_D143V. Previously Burger et al [93] also demonstrated that PTX only 
partially (approx. 50%) prevents IP3 accumulation mediated by CXCR2_D143V 
so our data match this previous publication. Surprisingly, CXCR2_D9H and D9K 
show PTX independent foci formation implying that they not inducing the same 
pathways as WT_CXCR2 or CXCR2_D143V.  CXCR2_D9R showed no 
statistical difference with both WT_CXCR2 and CXCR2_D143V showing that this 
is mutant is using a different pathway in spite of showing similar foci formation 
with D9H and D9K. U73122 differentially inhibits foci formation mediated by 
CXCR2 CAMs as well as WT_CXCR2 activation (Figure 18-B).  
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Figure 118. Inhibitors define differential signal transduction pathways for 
CXCR2 CAMs during foci formation.  
 Foci formation assay was performed in the presence of specific signal 
transduction inhibitors: (A) PTX (100nM) for Gαi, (B) U73122 (2µM) for PLC-β, 
and (D) AG490 (50µM) for JAK. Foci formation of WT_CXCR2 was induced with 
IL-8 (100nM) stimulation as a positive control. Percentage reduction was 
expressed as (the number of foci in the untreated samples- the number of foci in 
the inhibitor treated samples / the number of foci in the untreated samples)x 100 
**is this right? Statistical analysis using Student’s t-test (PRISM (version 5.0b) 
was explained in the text. 
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There is a statistically significant difference for CXCR2_D143V, D9H, and D9K 
except D9R (p>0.05) compared with WT_CXCR2. Comparing with 
CXCR2_D143V and others indicated that CXCR2_D9H, D9K and D9R are not 
statistically significant implying that they are using PLC β as part of their signaling 
repertoire. 
 A number of CXCR2 CAMs, such as CXCR2_D9H, D9K and D9R, 
showed a different combinational effect with both PTX and U73122 (Figure 18-
C). However, CXCR2_D143V only showed either PTX or U73122 dependent foci 
formation not a combinational effect. Statistically CXCR2_D143V (p<0.05) and 
D9H (p<0.05) showed a significant difference compared with WT_CXCR2. Only 
CXCR2_D9H (p>0.05) presented is statistically significant compared with 
CXCR2_D143V showing that this is using yet another more complex pattern of 
signaling.  
 Interestingly, AG490 completely inhibited foci formation for WT_CXCR2 
(Figure 18-D) and others indicating that the JAK-STAT signaling pathway is 
directly involved in cellular transformation. This is a parallel result with a previous 
study that showed AG490 completely prevented foci formation for WT_CXCR2 
and CXCR2_D143V [114]. Taken together these data suggest that WT_CXCR2 
and CXCR2 CAMs potentially activate Gαi and Gαq mediated signaling pathways. 
In addition to Gα protein mediated signaling, the JAK-STAT signaling pathway 
probably contributes to foci formation in a G protein independent manner. 
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CXCR2 CAMs induction of constitutive PLC-β3 activation  
 Since CXCR2 CAMs demonstrated U73122 dependent foci formation, 
activation of PLC β was tested to determine if the CXCR2 CAMs induce this 
signaling pathway.  Phosphatidylinositol phospholipase C (PLC) plays an 
important role in the induction of receptor mediated signal transduction through 
the origination of the two kinds of secondary messengers that are inositol 1,4,5-
triphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol 4,5 
biphosphate (PI2P) [231, 232]. There are a number of PLC isoforms that have 
been described, such as PLC β1, PLC β2, PLC β3, PLC β4, PLC γ1, PLC γ2, 
PLC δ1 and PLC δ2 [233]. Among these isoforms, the Gαq/11 family and certain 
Gβγ subunits activate PLC β1, PLC β2 and PLC β3, and PLC β3 is 
phosphorylated on Ser537 in the basal state [234-236]. Also IP3 and DAG 
accumulation leads to intracellular Ca2+ release, which causes phosphorylation of 
the protein kinase C (PKC) family [237, 238]. Therefore, modulation of PLC β3 
and PKC mediated by CXCR2 CAMs was investigated by FACs analysis with 
phospho-specific PLC β3 (Ser537) and PKC (α/β2) antibodies. Figure 19A shows 
dephosphorylation of PLC β3 for WT_CXCR2 stimulated by IL-8 (100 nM) after 
the cells were synchronized (serum starved). As mentioned above PLC β3 is 
phophorylated on Ser537 in the basal state in cells. Therefore interaction 
between WT_CXCR2 and IL-8 possibly induce PLC β3 activation (p<0.05). In 
addition to WT_CXCR2, CXCR2 CAMs induced differential PLC β3 activation. 
Interestingly, CXCR2_D9K (p<0.05) and D9H (p<0.05) activated PLC β3 more 
than WT_CXCR2 stimulated by IL-8.  
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Figure 119. CXCR2_CAMs induce differential signal transduction pathways 
through PLC β and PKC. 
Stably transfected NIH 3T3 cells were serum starved, permeablized, and stained 
with phospho-PLC β3 specific antibody (A and B) (Santacruz Biotech) and 
phospho-PKC specific antibody (D) (Cell Signaling). Induction of wild type 
CXCR2 was performed with IL-8 (100nM) after serum starvation. Stained cells 
were analyzed by FACs analysis (BD FACSCalibur). Data is representative of 
three independent experiments. Student’s t-test (PRISM (version 5.0b) was used 
to determine statistical significance (*; p< 0.05) (C and E). 
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 However CXCR2_D9N still remained at a basal level of PLC β3 phosphorylation 
(p>0.05, Figure 19B and C). 
 As mentioned above, PLC β3 activation induces PKC phosphorylation. 
Figure 19D and E indicated CXCR2_D143V (p<0.05) and D9K (p<0.05) lead to 
phosphorylation of PKC, which means PKC is a potential downstream signaling 
pathway for both CXCR2 CAMs. Taken together CXCR2 CAMs potentially utilize 
the Gαq/11 family and one of downstream target pathway is PKC.  
 
CXCR2 CAMs Transactivation of  Epidermal Growth Factor 
Receptor (EGFR)  
 The epidermal growth factor receptor (EGFR) activates several signaling 
cascades in response to epidermal growth factor stimulation. One of these 
signaling events involves JAK activation [239]. Since CXCR2 CAMs use JAK 
dependent foci formation, the potential transactivation of EGFR was investigated. 
 To identify the IL-8 or CXCR2 CAMs mediated transactivation pathway, 
the phosphorylation state of the EGFR was assessed in stably transfected 
NIH3T3 cells using a phospho-EGFR specific antibody (pY1173, BD 
Biosciences). Figure 20 shows that CXCR2 CAMs differentially phosphorylate 
EGFR. There is a also the possibility of autocrine EGFR phosphorylation 
mediated by secreted EGF.  To test this possibility, a mouse specific ELISA 
assay was used to measure the concentration of mouse EGF. The concentration 
of EGF was below the detection limit of 3 pg/ml indicating EGF independent 
EGFR transactivation. 




Figure 20. CXCR2 CAMs induce EGF independent EGFR phosphorylation. 
(A) Stable transfectants were serum starved, permeablized, and stained with 
phospho-EGFR specific antibody (pY1173, BD Biosciences). Stained cells were 
analyzed by FACs analysis (BD FACSCalibur). Data is representative of three 
independent experiments. (B) Student’s t-test (PRISM (version 5.0b) was used to 
determine statistical significance (*; p< 0.05). 
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EGFR transactivation mediated by heterotrimeric G protein, Gαi  
 CXCR2 activation mediated by IL-8 stimulation led to EGFR 
transactivation through heparin binding EGF (HB-EGF) [240]. Also, IL-8 
stimulation of cathepsin B expression involved HB-EGF activation [240]. Since 
the EGF concentration was undetectable, it is possible that there is a 
transactivator that signals from the CXCR2 CAMs to EGFR. To investigate the 
possible connection between CXCR2 CAMs and EGFR phosphorylation, the 
CXCR2_D9R, which highly transactivated EGFR, and CXCR2_D9K, a more 
modest transactivator of EGFR were treated with PTX and EGFR 
phosphorylation assessed. In Figure 21, PTX inhibited CXCR2_D9R/EGFR 
transactivation suggesting that Gαi subunit is involved in EGFR transactivation. 
 
CXCR2 CAMs Stimulation of NF-κB transcriptional activity  
 A number of studies have shown that GPCR CAMs stimulate NF-κB 
transcriptional activity, which induces cellular transformation in vitro 




Figure 21. CXCR2_D9R induce Gαi mediating EGFR transactivation. 
NIH3T3 cell stably expressing WT_CXCR2, D9K and D9R were serum starved in 
the presence of PTX (100ng/ml) for Gαi mediated signal transduction. Cells were 
permeablized, and stained with phospho-EGFR specific antibody (pY1173, BD 
Biosciences). Stained cells were analyzed by FACs analysis (BD FACSCalibur). 
Data is representative of three independent experiments. (D) Student’s t-test 
(PRISM (version 5.0b) was used to determine statistical significance (*; p< 0.05). 




Figure 22. CXCR2 CAMs induce differential basal levels of NF-κB  
HEK 293 cells were co-transfected with luciferase reporter constructs for NF-κB. 
For each transfection, luciferase activity was normalized for transfection 
efficiency and measured with Dual-GloTM luciferase assay system (Promega). 
Bars represent the average of three independent experiments +/-standard 
deviation (* p≤ 0.05).  
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and vivo [229, 241, 242]. In Figure 22, the basal level of NF-κB transcriptional 
activity was assessed for WT_CXCR2 and CXCR2 CAMs using a luciferase 
reporter assay. All CXCR2 CAMs induced NF-κB transcriptional activity except 
mock control and WT_CXCR2. Although CXCR2_D9N did not induce any 
phenotypic cellular transformation, the basal level of NF-κB transcriptional activity 
indicated CXCR2_D9N induces constitutive NF-κB transcriptional activity. Thus, 
there was no correlation between level of cellular transformation and NF-κB 
activity. 
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 CHAPTER 5. DISCUSSION 
 
 The results from this study suggest that CXCR2 CAMs initiate the 
activation of intracellular signal transduction cascades through multiple G 
proteins usage, which are Gαi and Gαq/11 families (Figure 18). Surprisingly a 
single point mutation in N-terminal 9th residue of CXCR2 caused this event.  
Classically, CXC chemokine receptors were suggested to mediate 
intracellular signaling through Gαi [93, 243]. Treatment of CXCR2 expressing 
cells line with PTX completely disrupted IL-8 mediated inhibition of forskolin-
stimulated cyclic AMP accumulation, which indicates CXCR2 activation induces a 
Gαi family dependent signal transduction pathway [153]. This Gαi dependent 
signaling stimulates the accumulation of intracellular inositol phosphate and 
increases intracellular calcium [150]. This induces a cascade of downstream 
intracellular signaling pathways for cellular proliferation, migration, and inhibition 
of apoptosis, and activation of NF-kB pathways [154-157]. Interestingly, our 
results suggest a different view of Gα protein family usage for chemokine 
receptors. WT_CXCR2 stimulated with IL-8 and CAMs probably induces a Gαq/11 
mediating signaling as well as Gαi. CXCR2 activation mediated by IL-8 
stimulation or CAMsexcept CXCR2_D9N, triggered differential PLC β3 and PKC 
activation (Figure 19), and activates NF-κB transcription activation (Figure 22). 
These G protein-dependent signal pathways, Gαq/11 – PLC β – PKC, and NF-κB 
activation are also shown in virally encoded GPCR CAMs. Other virally encoded 
CAMs such as human cytomegalovirus (HCMV)-encoded chemokine receptor, 
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US28 [241, 244] and murine cytomegalovirus-encoded GPCR homologue, M33 
[229] use Gαq/11 followed by PLC β and PKC activation [241, 245].  
 Interestingly, CXCR2_D9R potentially uses both Gαi and Gαq/11 proteins 
cooperatively (Figure 18). Recently, promiscuous G protein usage was reported 
by Kaposi’s sarcoma herpes virus (KSHV)-encoded GPCR, ORF74, which is a 
homologue of human CXCR2 [197]. In primary effusion lymphoma (PEL)-derived 
cell lines, KSHV ORF74 activates ERK and p38, and AP-1, NF-κB, CREB (cyclic-
AMP-response-element-binding protein) and NFAT (nuclear factor activator of T 
cells) transcriptional factors concommitantly with Gαq/11 and Gαi. KSHV ORF74 
utilized Gαi that induced AP-1 and CREB transcriptional activation via PI3K/Akt-
Src intracellular pathways. Gαq/11 usage of KSHV ORF74 led to transcriptional 
activation of AP-1, CREB, and NFAT via ERK-1/2. However, NF-κB 
transcriptional activation is probably mediated by not Gαi but Rac 1 [197]. 
Additionally US28 potentially uses promiscuous G-protein in a similar fashion 
with KSHV ORF74 [102, 246]. US28 showed that Gαq/11 and Gβγ activate NF-κB 
indicting a modulation of transcriptional factors through differential G protein 
usage. Taken together, CXCR2_D9R seems to modulate multiple signal 
transduction cascades through Gαq/11 and Gαi usage not like other CXCR2 CAMs 
but like viral GPCR CAMs, which induces a potent of cellular transformation. 
 The mutation of the DRY motif from aspartic acid (D) to valine (V) at the 
junction of third TM domain and intracellular loop was the first identified CXCR2 
CAM [93]. The CXCR2 mutation in the DRY motif resulted in anchorage 
independent growth and loss of contact inhibition. However, this result is quite 
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reasonable due to the importance of D/ERY motif for G protein activation. In 
addition to D/ERY motif, mutation or deletion of a non-TM region, such as a large 
ectodomain [81, 97] and C-terminal intracellular domain [98], induces constitutive 
activity. Our study is the first to describe an N-terminal single point mutation 
causing chemokine receptor constitutive activity. One possible explanation is a 
gain-of function phenotype induced by the loss of an intramolecular interaction 
suggested by Kjelsberge et al [87]. In their study, mutation of Ala293 to one of 
the 19 other amino acids in the α1B-adrenergic receptor resulted in constitutive 
activation. Based on this report, they established propose a structural constraint 
that maintains the receptor in the inactive state. Another possible explanation of 
an N-terminal point mutation inducing CAM is the gain of intramolecular 
interaction that induces differential activation. To confirm the mechanism for 
constitutive activation mediated by N-terminal point mutations, additional 
biochemical and biophysical studies will be necessary. 
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CHAPTER 6. SUMMARY AND CONCLUSIONS 
 
 Much evidence suggests that CXCR2 activation is involved various types 
of cancer development and metastasis. To elucidate CXCR2 activation and its 
relationship with tumorigenesis, CXCR2 constitutively active mutants were 
screened using a genetically modified Saccharomyces cerevisiae high-
throughput system. Surprisingly, a single point mutation in N-terminal 9th residue 
of CXCR2 led to constitutive activity, which motivated generating positive 
charged substitutions, D9K and D9R, and D143V as a positive control for a 
known CXCR2 CAM. Stably transfected NIH3T3 cells expressing CXCR2 CAMs 
demonstrate the loss of contact inhibition and anchorage independent growth, 
which are two characteristics of cell that have undergone cellular transformation. 
Since the PLC β inhibitor U73122 and the Gαi inhibitor PTX were able to prevent 
cellular transformation, PLC β and Gαi mediated signal transduction pathways 
were investigated further. Interestingly, both IL-8 stimulation of WTCXCR2 and 
the CXCR2 CAMs induced constitutive PLC β activation indicating that the Gαq/11 
subunit family are involved. Additionally, CXCR2 CAMs induced differential basal 
levels of NF-κB. Although CXCR2_D9N showed weak ability for cellular 
transformation, NF-κB transcriptional activity showed higher levels than D9K and 
D9R suggesting a high degree of cellular transformation. Using the inhibitor 
AG490, the JAK pathway was shown to be directly involved cellular contact 
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inhibition. Also, CXCR2 CAMs were demonstrated to transactivate EGFR in a 
PTX sensitive fashion suggesting Gαi associated transactivation of EGFR.  
 Taken together, CXCR2 CAMs mediate constitutively activated 
intracellular signaling pathways, which are proposed in Figure 23. Our model, 
based on our data, shows a complex relationship between CXCR2 activation, 
downstream signaling and phenotypic readouts.  Treatment of cells with the 
inhibitor for PLC β, U73122, showed that IL-8 stimulated WT_CXCR2 and 
CXCR2 CAMs, such as D143V, D9H, D9K and D9R, induce Gαq/11 stimulation of 
the PLC β pathway. All CAMs including CXCR2_D9N activate NF-κB 
transcription. In the case of CXCR2_D9N, heterotrimeric G protein usage was 
not investigated due to weak growth and low numbers of foci. However, low 
activity in loss of contact inhibition and anchorage independent growth assays 
potentially indicate that NF-κB activation may be involved in cell survival. 
Because foci are still induced after using both U73122 and PTX inhibitors it is 
possible that D143V and D9H possibly utilize another Gα family or the Gβγ 
proteins, which are also capable of mediating downstream signal transduction 
pathways. Interestingly, a specific inhibitor of JAK signaling, AG490, inhibited all 
foci formation in all mutants tested.  This strongly suggests that JAK-mediated 
signaling is a pathway involved in cellular transformation. In order to investigate 
where this signaling is initiated, we treated CXCR2_D9R with the EGFR specific 
inhibitor, butain.  In this case all foci formation was abolished.  This demonstrated 
that this specific EGFR-mediated signal transduction pathway is involved in 
cellular transformation.  This provides yet another pathway that contributes to foci 
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formation.  In summary, our data shows that CXCR2 can use multiple Gα 
proteins and that the CXCR2 CAMs can capture the differential activation states 
and signaling pathways.  Lastly, activation of CXCR2 leads to activation of the 
EGFR receptor though an internal transactivation cascade. This internal 
activation differentially transactivates EGFR in a PTX sensitive manner implying 
the Gαi protein is the mediator of this activation. Additionally, a number of studies 
suggest that EGFR activation potentially induces either JAK-independent or JAK-
dependent signalling through STAT1 or 3. 





Figure 22. Model for CXCR2 CAM induction of ligand-independent signal 
transduction cascades. 
 Based on our data, CXCR2 CAMs, such as D143V, D9H, D9K and D9R, 
including WT_CXCR2 stimulated with IL-8, possibly utilize Gαq/11 followed by 
activation of PLC β. Interestingly, WT_CXCR2 stimulated with IL-8, D9R and 
D143V potentially use both Gαi and Gαq/11. Combinational treatment with U73122 
and PTX suggests D143V and D9H potentially induced constitutive signalling 
through another Gα famiy or Gβγ protein. Moreover it has been shown that PLC 
β can possibly be activated by Gβγ (blue dash line) [236]. Also all CXCR2 CAMs 
induced JAK-mediated signaling. D9R induced transactivatation of EGFR 
through Gαi. In addition it has been suggested that EGFR activation potentially 
induces either JAK-independent or JAK-dependent signalling through STAT1 or 
3 (orange dash line) [239, 247, 248].  
 Morphological cellular transformation was validated by loss of contact 
inhibition and anchorage-independent proliferation assays. All of the CXCR2 
CAMs except CXCR2_D9N showed both characteristics. CXCR2_D9N 
demonstrated only anchorage-independent growth. 
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Constitutive Activity of Other CXCR2 Mutants in the Yeast 
 
Introduction 
 As shown in part 4, genetically modified yeast encoding a part of 
mammalian Gα protein sequence was used to screen a CAMs and the b 
glactosidase activity was used to measure the degree of constitutive activity. This 
appendix presents data for other CXCR2 mutants that we generated including 
single point mutations, such as D9E, D9A, D9S and D9Y.   Deletion mutants that 
delete only the single D9 residue (ΔD9) and truncation mutants, such as Tru D9 
truncate up to the 8th residue (serine), Tru S10 truncated through the 9th residue 
(aspartic acid) and Tru C39 truncated to 38th residue (proline), which leaves the 
cysteine residue intact. 
 
Materials and methods 
 The experimental procedures are same as described in part 4 of chapter 3.	  
 
Results 
 All mutants show very similar activity when compared with WTCXCR2 
(Figure 24) except for D9A and D9Y albeit these mutants were much lower than 
the positive control, D143V.  These data show that not all mutations/truncations 
within CXCR2 lead to constitutive activity in yeast.  The next question that we 
wanted to address is whether the lack of constitutive activity in these mutants is 
also found in mammalian cells.  






Figure 23. Constitutive activity of CXCR2 mutants measured via β-
galactosidase activity in yeast.  
 Yeast strain, CY1141, contains the plasmid, pMD1325, which has the  
lacZ under the control of the pheromone responsive promoter. β-galactosidase 
activity was measure using the yeast β-galactosidase assay kit (Pierce) and 
represented in Miller units. Bars represent the average of three independent 
experiments plus/minus their standard deviation. Student’s t-test (PRISM(ver. 
5.0b)  was used to determine statistical significance (*; p≤ 0.05).  
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CXCR2 Mutants mediated Cellular Transformation 
 
Introduction 
 As shown in Chapter 4, CXCR2 CAMs differentially induced foci formation 
and anchorage-independent growth. This appendix presents the data about foci 
formation and soft-agar growth assays for other CXCR2 mutants. In addition to 
the mutations described early in this appendix, proline mutants, P266L and 
P266L/Y267L, were generated based on evidence from Konopka et al that 
showed mutations of residues Pro-258 and the adjacent Ser-259 to Leu leads to 
constitutive activity [1]. 
 
Materials and Methods 




 Foci formation and growth in soft agar were used as indicators of cellular 
transformation (Figure 24). As shown in Figure 24-A, only proline mutant, P266L, 
formed statistically significant (p<0.05) number of foci (approx. 55 foci) compared 
with WT_CXCR2, which indicates that the proline residue in TM6 plays an 
important role in maintaining CXCR2 in an inactive status. However, double 
mutant, P266L/Y267L, was not significantly different from WT_CXCR2. This 
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differs with previous data from Ste2p_P258L/S256L, which increased CA over 90% 
based on a β-galatosidase assay [1].  This could be due to the differences in 
these receptors, the different readouts (β-galatosidase assay vs foci formation) or 
the different cell types (yeast vs mammalian). 
 The soft-agar growth assay (Figure 24-B) demonstrated that deletion 
mutant, ΔD9, was much greater than background   (p<0.05) number of colony 
(20 colonies) albeit much lower than our previously described CXCR2 CAM.  All 
other mutants were not greater than WT_CXCR2 indicating they do not lead to 
constitutive activity. 
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Figure 24. CXCR2s CAMs lead to differential foci formation and anchorage 
independent growth.  
 As a measure of their ability to transform cells, foci formation (A) and 
anchorage-independent growth (B) of stably transfected NIH3T3 cells expressing 
WT_CXCR2 or CXCR2 mutants in the presence of CXCR2 antagonist 
(SB225002, 1 µM) were measured. Bars represent the average of three 
independent experiments +/- standard deviation. Student’s t-test (PRISM (version 
5.0b) was used to determined statistical significance versus CXCR2_WT (*; 
p<0.05).  
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CXCR2 Mutants and Ligand Binding  
 
Introduction 
 To address whether the mutations in CXCR2 eliminated ligand binding, a 
competition binding assay was performed to measure relative binding affinity.   
 
Materials and Methods 
 Transiently transfected Cos-7 cells were seeded in a 48-well plate. At 48 
hours post transfection, binding was performed on whole cells for 3 to 4 h at 4 oC 
with125I-IL-8 in a binding buffer (50mM HEPES (pH7.4), 1mM CaCl2, 5mM 
MgCl2, 0.5% bovine serum albumin). After incubation, cells were washed four 
times with ice-cold binding buffer supplemented with 0.5M NaCl. Cells were 
collected and counted in a Wallac Compugamma counter. 
 
Result 
 All mutants except for the E198A and the double mutants used for other 
experiments showed normal binding.  This shows that the CXCR2 CAMs did not 
alter binding to ligands and the alteration in conformation that leads to 
constitutive activity does not affect the binding pocket.  We have also carried out 
our transformation assays in presence of ligands and saw no increase in foci or 
colony formation (data not shown).  
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IL-8 Binding Assay 
[radioligand] = 0.2-0.4 nM 
Receptor IC50 CXCL8 n 
WT 8.92 ± 0.05 8 
ΔD9 9.01 ± 0.06 4 
D9A no binding 2 
D9E no binding 4 
D9H 8.73 ± 0.09 7 
D9K 8.56 ± 0.05 2 
D9N 8.75 ± 0.18 3 
D9R 8.69 ± 0.21 3 
D9S 8.71 ± 0.06 3 
D9Y 8.81 ± 0.16 4 
E198A 
 
no binding 4 
D199A 
 
8.82 ± 0.20 4 
E198A/D199A no binding 4 
D9K/E198A no binding 1 
D9K/D199A no binding 1 
D9K/E198A/D199A no binding 1 
D143V 9.28 ± 0.06 4 
R144A 9.13 ± 0.11 4 
II250-251ins 8.65 ± 0.14 3 
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CXCR2 CAM induction of Tumor Formation in vivo 
 
Introduction 
 To address whether CXCR2_CAMs induce tumor formation in vivo, 
transfectants were injected into the hind flanks  of mice and the size of the tumor 
was measured over time. Stable NIH3T3 transfectants were inoculated into nu/nu 
mice (Jackson Laboratory) and Melan-a transfectants into C57BL6 mice 
(Jackson Laboratory). The Melan-a cell line is a prototype of melanocytes and 
was originally derived from C57/BL6 mice [2].  These transfectants were 
generated to model melanoma development and allowed us to assess tumor 
development in the context of an immune competent mouse. 
 
 
Materials and Methods 
 
 CXCR2 stable transfectants or untransfected controls (2×105/mice) were 
injected subcutaneously into the flanks of 6 to 8 wk old nu/nu mice (Jackson 
Laboratory) and C57BL6 mice (Jackson Laboratory). Tumor size was measured 
using a digital caliper. The protocol for animal experiment was reviewed and 
approved by the Institutional Animal Care and Concerns Committee of the 
University of Tennessee. 
 
Results 
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 Our data shows that even WT_CXCR2 can form tumors in vivo.  This 
could be do to ligand engagement of the WT_CXCR2 receptor that contributes to 
tumor growth.  The in vivo administration of the CXCR2 inhibitor SB225002 did 
not alter the growth of the tumors.  There are multiple reasons for this.  First, 
there is no information about the bioavailability of this small molecule inhibitor.  
Second, there is the possibility that once these cells have become transformed, 
they no longer need ligand stimulation.  There are several other possibilities for 
this negative outcome.  In the initial experiments using the Melan-A transfectants 
only the D9N transfectant consistently formed tumors (Figure 29).  In the repeat 
experiment the D9N transfectants still showed significant tumor growth, but due 
to tumor growth in some of the mice inoculated with untransfected controls, these 
data are not significantly different (Figure 30).    Although these experiments 
have led to confusing results, there is a definite trend towards D9N CXCR2 
Melan-a transfectants leading to tumor growth.  If we are able to definitively 
demonstrate this, it could mean that the D9N CXCR2 conformation stimulates 
signaling pathways that contribute to tumor growth in this cell line while the other 
CXCR2 CAMs do not.  Only after further experimentation will we be able to make 
this conclusion. 
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Figure 25. Differential tumor formation in nu/nu mouse. 




Figure 26. Differential tumor formation in nu/nu mouse. 
 In a similar experiment, nu/nu mice were injected and some of the mice 
were also injected with the CXCR2 inhibitor (I), SB225002, (1 mg/kg, i.p.) once 
per a week. 
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Figure 27. Effect of SB225002 for tumor formation in nu/nu mice 
Note: WT CXCR2+I represents CXCR2 inhibitor, SB225002, injection into the 
mouse (1 mg/kg, i.p.) once per week for the duration of the experiment. 




Figure 28. Differential tumor growth in nu/nu mice over time. 
Weekly the size of the tumor (length x width) was measured.  Bars represent the 
average size of the tumors +/- standard deviation.  Note: A “Dead Receptor”, 
CXCR2_R144A, was used as an additional negative control.  This receptor can 
not respond to ligand. 



















Figure 29. D9N_CXCR2 transfectant leads to a more robust and early tumor 
formation in BL6 mice.   
 After inoculation, whole groups of mice were removed from the study 
when one mouse in group had a tumor size greater than 1.5 cm.  At the time of 
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Figure 30. Differential tumor formation in C57/BL6 mice.   
 In a repeat experiment, tumor volume was measured.  Bars represent the 
average tumor volume +/- standard deviation. 
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Establishment of Stable Cancer Cell Lines Overexpressing wild 
type CXCR2 and CXCR2 Mutants  
 
Introduction 
 As shown in part 4, mouse fibroblast cell line, NIH3T3, is a common cell 
line used to address the cellular transformation potential of a protein. Both foci 
formation and soft-agar growth assays show their relative transformed state. 
However, in order to assess the real potential of CXCR2 CAMs in cancer 
development, these proteins need to be analyzed in a real cancer environment. 
Therefore, we established stable cell lines that express WT_CXCR2 and CXCR2 
CAMs in human adenocarcinoma cells, A549, and androgen independent and 
highly metastatic prostate cancer cell line, PC-3. 
 
Materials and methods 




 FACs analysis of stable cancer cell lines expressing WT_CXCR2 and 
CXCR2 CAMS shows equal expression in both lines (Figure 25). Clones were 
selected and used in our different assays. 





Figure 31. CXCR2 surface expression on stable transfectants.  
 Stable A549 and PC-3 transfectants were selected and stained with PE 
conjugated CXCR2 specific antibody (R&D Systems, Cat.No. FAB331P). 
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Differential Adhesion Molecule Expression in A549 stable lines 
 
 In order for cancers to metastasize, cancer cells may lose and/or gain 
adhesive interactions in order to spread throughout the body. Adhesion 
molecules, such as cadherins and cell adhesion molecules (CAMs), play an 
important role the metastatic process [248]. The cadherins are membrane 
glycoproteins that function in adherence in a calcium-dependent manner [249, 
250]. One of the cadherins, E-cadherin, is expressed on epithelial cells and 
maintains intracellular adhesion, so E-cadherin reversely correlates with cancer 
cell metastasis [248]. Intercellular adhesion molecule-1 (ICAM-1) is the ligand for 
LFA-1, an integrin found on leukocytes [251]. Activation of ICAM-1 induces 
leukocyte binding to the endothelium through ICAM-1/LFA-1 interaction 
eventually leading to transmigration into tissues [252]. MCAM is a melanoma cell 
adhesion molecule and is used as a marker of the endothelial lineage [253]. 
MCAM is associated actin cytoskeletal rearrangements and plays a role in cell-
cell adhesion [254-256]. In order to address the role of CXCR2 stimulation in 
cancer metastasis, our CXCR2 expressing A549 stable cell lines were stimulated 
with the CXCR2 ligand, Gro-α, and the levels of different adhesion molecules 
were measured.  
 
Materials and Methods 
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 To observe the changes in adhesion molecule expression, A549 and A549 
transfectants expressing either WT_CXCR2 or CXCR2_D9N were either serum 
starved for 24 hours or starved and then stimulated with Gro-α (10nM) for the 
final four hours. Harvested cells were stained with specific antibodies for ICAM, 
MCAM, or N-cadherin (BD Biosciences). After staining, cells were washed, fixed 




 A549 cell lines express CXCR1 but not CXCR2 but expression (Dr. Masi, 
personal communication). Stable lines were stimulated with Gro-α as it only 
stimulates CXCR2. The levels of adhesion molecule expression was measured 
via flowcytometry as shown in Figure 26. ICAM is up regulated upon serum 
starvation but down regulated upon Gro-α stimulation. In contrast, MCAM is only 
upregulated in the CXCR2_D9N stimulated with Gro-α. E-Cadherin is 
upregulated equally throughout. This demonstrates that over-expression and 
stimulation of WT or D9N_CXCR2_ in adenocarcinomas can affect cellular 
adhesion molecule expression that could relate to their metastatic ability. 
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Figure 32. Alteration of adhesion molecule expression in CXCR2 
expressing A549 stable lines upon exposure to Gro-α.   
 A549 lung cancer line transfectants were serum starved for 24 hours  and 
then stimulated with Gro-α (10nM) or mock  for the final four hours.  Cells were 
then stained with the directly conjugated antibodies against the adhesion 
molecules listed above.    Colored lines are Gro-α stimulated, black lines are 
serum starved alone, and gray lines are unstained controls. 
 
	   161	  
VITA 
	  
 Giljun Park was born in Seoul, Korea on January 22, 1975. He entered the 
Yonsei University, Seoul, Korea, in March 1993 and graduated with a Bachelor 
degree in Biology in February 2000. He started his graduate study at the Seoul 
National University in 1999 and graduated his master-thesis program in 
Oceanography in 2003. In January of 2004, he entered Graduate School at the 
University of Tennessee in Microbiology. Throughout the course of his time in 
this program, he served as a Graduate Teaching Assistant (2004-2007 and 
2010) and as a Graduate Research Assistant (2008-2009). He officially received 
a Doctor of Philosophy degree in Microbiology in December 2010. 
